



Clinical trial results:

A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with advanced HER3-positive solid tumors

Summary

EudraCT number	2013-001699-39
Trial protocol	NL
Global end of trial date	18 September 2017

Results information

Result version number	v2 (current)
This version publication date	20 April 2019
First version publication date	15 September 2018
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	117158
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 January 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	18 September 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine the safety and tolerability of GSK2849330 in participants with advanced Human epidermal growth Factor Receptor 3 (HER3)-positive solid tumors.

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	26 November 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 17
Country: Number of subjects enrolled	Netherlands: 7
Country: Number of subjects enrolled	United States: 5
Worldwide total number of subjects	29
EEA total number of subjects	7

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	17
From 65 to 84 years	11
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

This is a Phase 1 study of anti-human epidermal growth factor receptor 3 (HER3) antibody, GSK2849330 in participants with advanced solid tumors expressing HER3. The study was conducted in 2 parts-Part1 (dose escalation) and Part2 (dose expansion). The starting dose in Part1 was 1.4 milligrams per kilogram (mg/kg) GSK2849330 given weekly for 28 days

Pre-assignment

Screening details:

A total of 29 participants were randomized. The study was conducted in three countries. Participants in the GSK2849330 30 mg/kg weekly arm were not double counted with any other Arm.

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	GSK2849330 1.4 mg/kg weekly
------------------	-----------------------------

Arm description:

Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days

Arm type	Experimental
Investigational medicinal product name	GSK2849330
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

Arm title	GSK2849330 3 mg/kg every 2 weeks
------------------	----------------------------------

Arm description:

Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

Arm type	Experimental
Investigational medicinal product name	GSK2849330
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

Arm title	GSK2849330 3 mg/kg weekly
------------------	---------------------------

Arm description:

Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.

Arm type	Experimental
Investigational medicinal product name	GSK2849330
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

Arm title	GSK2849330 10 mg/kg every 2 weeks
------------------	-----------------------------------

Arm description:

Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

Arm type	Experimental
Investigational medicinal product name	GSK2849330
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

Arm title	GSK2849330 30 mg/kg every 2 weeks
------------------	-----------------------------------

Arm description:

Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days

Arm type	Experimental
Investigational medicinal product name	GSK2849330
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

Arm title	GSK2849330 30 mg/kg weekly
------------------	----------------------------

Arm description:

Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days.

Arm type	Experimental
Investigational medicinal product name	GSK2849330
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

Number of subjects in period 1	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly
Started	1	3	2
Completed	1	1	1
Not completed	0	2	1
Consent withdrawn by subject	-	1	1
Physician decision	-	1	-
Lost to follow-up	-	-	-

Number of subjects in period 1	GSK2849330 10 mg/kg every 2 weeks	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly
Started	5	4	14
Completed	2	1	8
Not completed	3	3	6
Consent withdrawn by subject	-	2	2
Physician decision	1	1	3
Lost to follow-up	2	-	1

Baseline characteristics

Reporting groups

Reporting group title	GSK2849330 1.4 mg/kg weekly
Reporting group description: Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days	
Reporting group title	GSK2849330 3 mg/kg every 2 weeks
Reporting group description: Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.	
Reporting group title	GSK2849330 3 mg/kg weekly
Reporting group description: Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.	
Reporting group title	GSK2849330 10 mg/kg every 2 weeks
Reporting group description: Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.	
Reporting group title	GSK2849330 30 mg/kg every 2 weeks
Reporting group description: Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days	
Reporting group title	GSK2849330 30 mg/kg weekly
Reporting group description: Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days.	

Reporting group values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly
Number of subjects	1	3	2
Age categorical			
Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan (RAP).			
Units: Subjects			
Total	1	3	2
Age continuous			
99999 indicates standard deviation for 1.4 mg/kg weekly arm could not be calculated as only a single participant was analyzed in this arm.			
Units: years			
arithmetic mean	63.0	62.3	46.0
standard deviation	± 99999	± 4.04	± 21.21
Gender categorical			
Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.			
Units: Subjects			
Female	0	3	1
Male	1	0	1
Race/Ethnicity, Customized			
Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.			
Units: Subjects			
Race customized Asian-Central/South Asian Heritage	0	0	0

Race customized White	1	3	2
-----------------------	---	---	---

Reporting group values	GSK2849330 10 mg/kg every 2 weeks	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly
Number of subjects	5	4	14
Age categorical			
Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan (RAP).			
Units: Subjects			
Total	5	4	14
Age continuous			
99999 indicates standard deviation for 1.4 mg/kg weekly arm could not be calculated as only a single participant was analyzed in this arm.			
Units: years			
arithmetic mean	66.2	58.3	62.5
standard deviation	± 7.19	± 8.73	± 11.65
Gender categorical			
Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.			
Units: Subjects			
Female	2	2	5
Male	3	2	9
Race/Ethnicity, Customized			
Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.			
Units: Subjects			
Race customized Asian-Central/South Asian Heritage	0	0	1
Race customized White	5	4	13

Reporting group values	Total		
Number of subjects	29		
Age categorical			
Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan (RAP).			
Units: Subjects			
Total	29		
Age continuous			
99999 indicates standard deviation for 1.4 mg/kg weekly arm could not be calculated as only a single participant was analyzed in this arm.			
Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical			
Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.			
Units: Subjects			
Female	13		
Male	16		
Race/Ethnicity, Customized			
Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.			
Units: Subjects			
Race customized Asian-Central/South Asian Heritage	1		

Race customized White	28		
-----------------------	----	--	--

End points

End points reporting groups

Reporting group title	GSK2849330 1.4 mg/kg weekly
Reporting group description:	Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
Reporting group title	GSK2849330 3 mg/kg every 2 weeks
Reporting group description:	Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
Reporting group title	GSK2849330 3 mg/kg weekly
Reporting group description:	Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
Reporting group title	GSK2849330 10 mg/kg every 2 weeks
Reporting group description:	Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
Reporting group title	GSK2849330 30 mg/kg every 2 weeks
Reporting group description:	Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
Reporting group title	GSK2849330 30 mg/kg weekly
Reporting group description:	Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days.

Primary: Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Parts 1 and 2

End point title	Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Parts 1 and 2 ^[1]
End point description:	An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; and left ventricular ejection fraction (LVEF) meeting stopping criteria. AEs were collected in All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
End point type	Primary
End point timeframe:	Median of 6.143 weeks of drug exposure

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[2]	3 ^[3]	2 ^[4]	5 ^[5]
Units: Participants				
AEs	1	3	2	5
SAEs	0	1	0	1

Notes:

[2] - All Treated Population

[3] - All Treated Population

[4] - All Treated Population

[5] - All Treated Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[6]	14 ^[7]		
Units: Participants				
AEs	4	14		
SAEs	1	3		

Notes:

[6] - All Treated Population

[7] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with dose-limiting toxicities (DLTs)-Parts 1 and 2

End point title	Number of participants with dose-limiting toxicities (DLTs)- Parts 1 and 2 ^[8]
-----------------	--

End point description:

An event was considered a DLT if it occurred within the first 4 weeks (28 days) of treatment, and met one of the following criteria unless it could be established that the event was unrelated to treatment: Grade 3 or greater non-hematologic toxicity; Grade 4 neutropenia lasting >5 days; Febrile neutropenia, of any grade or duration; Grade 4 thrombocytopenia, or Grade 3 thrombocytopenia associated with bleeding; Alanine aminotransferase (ALT) >3 times upper limit of normal (ULN) with bilirubin >2 times ULN; Any Grade 2 or greater toxicity that in the judgment of the investigator and GlaxoSmithKline (GSK) Medical Monitor, would be considered dose-limiting; Grade 3 or greater decrease in LVEF. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

End point type	Primary
----------------	---------

End point timeframe:

Up to 28 days

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[9]	3 ^[10]	2 ^[11]	5 ^[12]
Units: Participants				
Participants	0	0	0	0

Notes:

[9] - All Treated Population

[10] - All Treated Population

[11] - All Treated Population

[12] - All Treated Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[13]	14 ^[14]		
Units: Participants				
Participants	0	0		

Notes:

[13] - All Treated Population

[14] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with grade change from Baseline in clinical chemistry data-Parts 1 and 2

End point title	Number of participants with grade change from Baseline in clinical chemistry data-Parts 1 and 2 ^[15]
-----------------	---

End point description:

Blood samples were collected for analysis of following parameters: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (Total bil), calcium, creatinine, gamma glutamyl transferase (GGT), glucose, potassium, magnesium, sodium, phosphorus, uric acid. Laboratory parameters were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Baseline was defined as most recent, non-missing value from central laboratory prior to or on first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. Data for worst-case post Baseline is presented. 99999 indicates data was not available. Only those participants with data available at specified time points were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

End point type	Primary
----------------	---------

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[16]	3 ^[17]	2 ^[18]	5 ^[19]
Units: Participants				
Albumin; any Grade increase; n=1,3,2,5,4,14	1	1	0	3
Albumin; increase to Grade 3; n=1,3,2,5,4,14	0	0	0	0
Albumin; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
ALP; any grade increase; n=1,3,2,5,4,14	1	0	1	1
ALP; increase to Grade 3; n=1,3,2,5,4,14	0	0	0	0
ALP; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
ALT; any Grade increase; n=1,3,2,5,4,14	0	2	0	2
ALT; increase to Grade 3; n=1,3,2,5,4,14	0	0	0	0
ALT; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
AST; any Grade increase; n=1,3,2,5,4,14	0	1	0	2
AST; increase to Grade 3; n=1,3,2,5,4,14	0	0	0	0
AST; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
Total bil; any Grade increase; n=1,3,2,5,4,14	0	1	0	1
Total bil; increase to Grade 3; n=1,3,2,5,4,14	0	0	0	0
Total bil; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
Calcium; any Grade increase; n=1,3,2,5,4,14	0	0	0	0
Calcium; increase to Grade 3; n=1,3,2,5,4,14	0	0	0	0
Calcium; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
Creatinine; any Grade increase; n=1,3,2,5,4,14	0	1	0	1
Creatinine; increase to Grade 3; n=1,3,2,5,4,14	0	0	0	0
Creatinine; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
GGT; any Grade increase; n=1,3,2,5,4,14	1	0	1	2
GGT; increase to Grade 3; n=1,3,2,5,4,14	0	0	1	1
GGT; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
Glucose; any Grade increase; n=1,3,2,5,4,14	1	0	1	3
Glucose; increase to Grade 3; n=1,3,2,5,4,14	0	0	0	0
Glucose; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
Potassium; any Grade increase; n=1,3,2,5,4,14	0	2	0	0

Potassium; increase to Grade 3; n=1,3,2,5,4,14	0	1	0	0
Potassium; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
Magnesium; any Grade increase; n=1,3,2,5,4,14	0	1	0	0
Magnesium; increase to Grade 3; n=1,3,2,5,4,14	0	0	0	0
Magnesium; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
Sodium; any Grade increase; n=1,3,2,5,4,14	0	1	0	0
Sodium; increase to Grade 3; n=1,3,2,5,4,14	0	0	0	0
Sodium; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
Phosphorus; any Grade increase; n=1,3,2,5,4,14	1	0	0	0
Phosphorus; increase to Grade 3; n=1,3,2,5,4,14	0	0	0	0
Phosphorus; increase to Grade 4; n=1,3,2,5,4,14	0	0	0	0
Uric acid; any Grade increase; n=0,0,0,0,0,1	99999	99999	99999	99999
Uric acid; increase to Grade 3; n=0,0,0,0,0,1	99999	99999	99999	99999
Uric acid; increase to Grade 4; n=0,0,0,0,0,1	99999	99999	99999	99999

Notes:

[16] - All Treated Population

[17] - All Treated Population

[18] - All Treated Population

[19] - All Treated Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[20]	14 ^[21]		
Units: Participants				
Albumin; any Grade increase; n=1,3,2,5,4,14	3	6		
Albumin; increase to Grade 3; n=1,3,2,5,4,14	0	1		
Albumin; increase to Grade 4; n=1,3,2,5,4,14	0	0		
ALP; any grade increase; n=1,3,2,5,4,14	1	7		
ALP; increase to Grade 3; n=1,3,2,5,4,14	1	1		
ALP; increase to Grade 4; n=1,3,2,5,4,14	0	0		
ALT; any Grade increase; n=1,3,2,5,4,14	3	6		
ALT; increase to Grade 3; n=1,3,2,5,4,14	0	0		
ALT; increase to Grade 4; n=1,3,2,5,4,14	0	0		
AST; any Grade increase; n=1,3,2,5,4,14	2	5		

AST; increase to Grade 3; n=1,3,2,5,4,14	0	1		
AST; increase to Grade 4; n=1,3,2,5,4,14	0	0		
Total bil; any Grade increase; n=1,3,2,5,4,14	0	2		
Total bil; increase to Grade 3; n=1,3,2,5,4,14	0	0		
Total bil; increase to Grade 4; n=1,3,2,5,4,14	0	0		
Calcium; any Grade increase; n=1,3,2,5,4,14	2	2		
Calcium; increase to Grade 3; n=1,3,2,5,4,14	1	0		
Calcium; increase to Grade 4; n=1,3,2,5,4,14	0	0		
Creatinine; any Grade increase; n=1,3,2,5,4,14	1	2		
Creatinine; increase to Grade 3; n=1,3,2,5,4,14	0	0		
Creatinine; increase to Grade 4; n=1,3,2,5,4,14	0	0		
GGT; any Grade increase; n=1,3,2,5,4,14	3	8		
GGT; increase to Grade 3; n=1,3,2,5,4,14	0	3		
GGT; increase to Grade 4; n=1,3,2,5,4,14	1	0		
Glucose; any Grade increase; n=1,3,2,5,4,14	2	4		
Glucose; increase to Grade 3; n=1,3,2,5,4,14	0	0		
Glucose; increase to Grade 4; n=1,3,2,5,4,14	0	0		
Potassium; any Grade increase; n=1,3,2,5,4,14	0	1		
Potassium; increase to Grade 3; n=1,3,2,5,4,14	0	0		
Potassium; increase to Grade 4; n=1,3,2,5,4,14	0	0		
Magnesium; any Grade increase; n=1,3,2,5,4,14	2	4		
Magnesium; increase to Grade 3; n=1,3,2,5,4,14	0	0		
Magnesium; increase to Grade 4; n=1,3,2,5,4,14	0	0		
Sodium; any Grade increase; n=1,3,2,5,4,14	3	4		
Sodium; increase to Grade 3; n=1,3,2,5,4,14	0	0		
Sodium; increase to Grade 4; n=1,3,2,5,4,14	0	0		
Phosphorus; any Grade increase; n=1,3,2,5,4,14	0	4		
Phosphorus; increase to Grade 3; n=1,3,2,5,4,14	0	0		
Phosphorus; increase to Grade 4; n=1,3,2,5,4,14	0	0		
Uric acid; any Grade increase; n=0,0,0,0,0,1	99999	1		
Uric acid; increase to Grade 3; n=0,0,0,0,0,1	99999	0		

Uric acid; increase to Grade 4; n=0,0,0,0,0,1	99999	1		
--	-------	---	--	--

Notes:

[20] - All Treated Population

[21] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with change from Baseline in clinical chemistry data with respect to normal range-Parts 1 and 2

End point title	Number of participants with change from Baseline in clinical chemistry data with respect to normal range-Parts 1 and 2 ^[22]
-----------------	--

End point description:

Blood samples were collected for analysis of following chemistry parameters: direct bilirubin (D.Bil.), cancer antigen (CA)-125, CA-15.3, CA19-9, chloride, carbon dioxide (CO₂)/bicarbonate (HCO₃), luteinizing hormone (LH), total protein and urea or blood urea nitrogen (BUN). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. A laboratory value that is outside the reference range was considered either high abnormal (value above upper limit of the reference range) or low abnormal (value below lower limit of the reference range). Data for worst-case post Baseline is presented. 99999 indicates data was not available. Only those participants with data available at specified time points were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP

End point type	Primary
----------------	---------

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[23]	3 ^[24]	2 ^[25]	5 ^[26]
Units: Participants				
D.Bil.; Decrease to Low; n=1,3,2,5,3,14	0	0	1	0
D.Bil.; increase to high; n=1,3,2,5,3,14	0	1	0	2
CA-125; Decrease to Low; n=1,3,0,5,4, 0	0	0	99999	0
CA-125; increase to high; n=1,3,0,5,4, 0	0	0	99999	0
CA 15.3; Decrease to Low; n=0, 0, 0, 0, 4, 0	99999	99999	99999	99999
CA 15.3; increase to high; n=0, 0, 0, 0, 4, 0	99999	99999	99999	99999
CA 19-9.; Decrease to Low; n=1,0,0,0,2,0	0	99999	99999	99999
CA 19-9; increase to high; n=1,0,0,0,2,0	0	99999	99999	99999
Chloride; Decrease to Low; n=1,3,2,5,4,14	0	1	0	1
Chloride; increase to high; n=1,3,2,5,4,14	0	0	0	0

CO2/HCO3.; Decrease to Low; n=1,3,2,5,4,14	0	0	0	3
CO2/HCO3.; increase to high; n=1,3,2,5,4,14	0	1	0	1
LH; Decrease to Low; n=1,0,2,3,2,7	0	99999	0	0
LH; increase to high; n=1,0,2,3,2,7	0	99999	0	0
Total Protein; Decrease to Low; n=1,3,2,5,4,14	0	1	1	1
Total Protein; increase to high; n=1,3,2,5,4,14	0	0	0	1
Urea/BUN; Decrease to Low; n=1,3,2,5,4,14	0	0	0	0
Urea/BUN; increase to high; n=1,3,2,5,4,14	0	1	1	0

Notes:

[23] - All Treated Population

[24] - All Treated Population

[25] - All Treated Population

[26] - All Treated Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[27]	14 ^[28]		
Units: Participants				
D.Bil.; Decrease to Low; n=1,3,2,5,3,14	0	0		
D.Bil.; increase to high; n=1,3,2,5,3,14	1	4		
CA-125; Decrease to Low; n=1,3,0,5,4, 0	0	99999		
CA-125; increase to high; n=1,3,0,5,4, 0	0	99999		
CA 15.3; Decrease to Low; n=0, 0, 0, 0, 4, 0	0	99999		
CA 15.3; increase to high; n=0, 0, 0, 0, 4, 0	0	99999		
CA 19-9.; Decrease to Low; n=1,0,0,0,2,0	0	99999		
CA 19-9; increase to high; n=1,0,0,0,2,0	0	99999		
Chloride; Decrease to Low; n=1,3,2,5,4,14	2	4		
Chloride; increase to high; n=1,3,2,5,4,14	0	1		
CO2/HCO3.; Decrease to Low; n=1,3,2,5,4,14	1	2		
CO2/HCO3.; increase to high; n=1,3,2,5,4,14	0	7		
LH; Decrease to Low; n=1,0,2,3,2,7	0	1		
LH; increase to high; n=1,0,2,3,2,7	0	3		
Total Protein; Decrease to Low; n=1,3,2,5,4,14	0	1		
Total Protein; increase to high; n=1,3,2,5,4,14	0	0		
Urea/BUN; Decrease to Low; n=1,3,2,5,4,14	1	3		
Urea/BUN; increase to high; n=1,3,2,5,4,14	0	2		

Notes:

[27] - All Treated Population

[28] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with grade change from Baseline in hematology data-Parts 1 and 2

End point title	Number of participants with grade change from Baseline in hematology data-Parts 1 and 2 ^[29]
-----------------	---

End point description:

Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, total neutrophils, platelet count, and white blood cell (WBC). The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. Number of participants with any grade increase, increase to Grade 3 and increase to Grade 4 in hematology data at worst-case post Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

End point type	Primary
----------------	---------

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[30]	3 ^[31]	2 ^[32]	5 ^[33]
Units: Participants				
Hemoglobin; any Grade increase	0	1	0	0
Hemoglobin; increase to Grade 3	0	0	0	0
Hemoglobin; increase to Grade 4	0	0	0	0
Lymphocytes; any grade increase	0	0	1	3
Lymphocytes; increase to Grade 3	0	0	0	0
Lymphocytes; increase to Grade 4	0	0	0	0
Total neutrophils; any Grade increase	0	0	0	1
Total neutrophils; increase to Grade 3	0	0	0	0
Total neutrophils; increase to Grade 4	0	0	0	0
Platelet; any Grade increase	0	1	1	0
Platelet; increase to Grade 3	0	0	0	0
Platelet; increase to Grade 4	0	0	0	0
WBC; any Grade increase	0	1	0	2
WBC; increase to Grade 3	0	0	0	0
WBC; increase to Grade 4	0	0	0	0

Notes:

- [30] - All Treated Population
- [31] - All Treated Population
- [32] - All Treated Population
- [33] - All Treated Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[34]	14 ^[35]		
Units: Participants				
Hemoglobin; any Grade increase	3	7		
Hemoglobin; increase to Grade 3	0	2		
Hemoglobin; increase to Grade 4	0	0		
Lymphocytes; any grade increase	1	5		
Lymphocytes; increase to Grade 3	0	2		
Lymphocytes; increase to Grade 4	0	0		
Total neutrophils; any Grade increase	0	1		
Total neutrophils; increase to Grade 3	0	0		
Total neutrophils; increase to Grade 4	0	0		
Platelet; any Grade increase	0	0		
Platelet; increase to Grade 3	0	0		
Platelet; increase to Grade 4	0	0		
WBC; any Grade increase	0	1		
WBC; increase to Grade 3	0	0		
WBC; increase to Grade 4	0	0		

Notes:

- [34] - All Treated Population
- [35] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with change from Baseline in hematology data with respect to normal range-Parts 1 and 2

End point title	Number of participants with change from Baseline in hematology data with respect to normal range-Parts 1 and 2 ^[36]
-----------------	--

End point description:

Blood samples were collected for the analysis of following hematology parameters: basophils, eosinophils, hematocrit, mean corpuscle hemoglobin concentration (MCHC), mean corpuscle hemoglobin (MCH), mean corpuscle volume (MCV), monocytes, red blood cell count (RBC) and reticulocytes. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as value at visit minus Baseline value. Number of participants with change from Baseline in hematology data at worst-case post Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

End point type	Primary
----------------	---------

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[37]	3 ^[38]	2 ^[39]	5 ^[40]
Units: Participants				
Basophils: decrease to low	0	0	0	0
Basophils: increase to high	0	0	0	0
Eosinophils: decrease to low	0	0	1	0
Eosinophils: increase to high	0	0	0	0
Hematocrit: decrease to low	0	0	0	1
Hematocrit: increase to high	0	0	0	0
MCHC: decrease to low	1	0	0	0
MCHC: increase to high	0	0	0	0
MCH: decrease to low	1	1	0	0
MCH: increase to high	0	0	0	0
MCV: decrease to low	0	1	0	0
MCV: increase to high	0	0	0	0
Monocytes: decrease to low	0	0	0	0
Monocytes: increase to high	1	0	0	0
RBC: decrease to low	0	0	0	3
RBC: increase to high	0	0	0	0
Reticulocytes: decrease to low	0	0	0	1
Reticulocytes: increase to high	0	0	0	1

Notes:

[37] - All Treated Population

[38] - All Treated Population

[39] - All Treated Population

[40] - All Treated Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[41]	14 ^[42]		
Units: Participants				
Basophils: decrease to low	0	0		
Basophils: increase to high	0	0		
Eosinophils: decrease to low	0	0		
Eosinophils: increase to high	0	2		
Hematocrit: decrease to low	1	4		
Hematocrit: increase to high	0	0		
MCHC: decrease to low	0	3		
MCHC: increase to high	0	0		
MCH: decrease to low	0	1		
MCH: increase to high	1	0		
MCV: decrease to low	0	1		
MCV: increase to high	0	1		

Monocytes: decrease to low	0	0		
Monocytes: increase to high	0	2		
RBC: decrease to low	0	7		
RBC: increase to high	0	1		
Reticulocytes: decrease to low	0	2		
Reticulocytes: increase to high	2	3		

Notes:

[41] - All Treated Population

[42] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with change from Baseline in urinalysis data with respect to normal range-Parts 1 and 2

End point title	Number of participants with change from Baseline in urinalysis data with respect to normal range-Parts 1 and 2 ^[43]
-----------------	--

End point description:

Urine samples were collected for the analysis of urine potential of hydrogen (pH) and urine specific gravity. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. The data for worst-case post Baseline is presented. Only those participants with data available at specified time points were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

End point type	Primary
----------------	---------

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[44]	3 ^[45]	2 ^[46]	5 ^[47]
Units: Participants				
Urine pH; decrease to low; n=1, 3, 1, 5, 4, 7	0	0	0	0
Urine pH; increase to high; n=1, 3, 1, 5, 4, 7	0	0	0	0
Specific gravity; decrease to low; n=1,3,1,4,4,8	0	1	0	0
Specific gravity; increase to high; n=1,3,1,4,4,8	1	0	0	0

Notes:

[44] - All Treated Population

[45] - All Treated Population

[46] - All Treated Population

[47] - All Treated Population

End point values	GSK2849330 30 mg/kg	GSK2849330 30 mg/kg		
------------------	------------------------	------------------------	--	--

	every 2 weeks	weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[48]	14 ^[49]		
Units: Participants				
Urine pH; decrease to low; n=1, 3, 1, 5, 4, 7	0	0		
Urine pH; increase to high; n=1, 3, 1, 5, 4, 7	0	1		
Specific gravity; decrease to low; n=1,3,1,4,4,8	0	0		
Specific gravity; increase to high; n=1,3,1,4,4,8	0	0		

Notes:

[48] - All Treated Population

[49] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with change from Baseline in vital signs-Parts 1 and 2

End point title	Number of participants with change from Baseline in vital signs-Parts 1 and 2 ^[50]
-----------------	---

End point description:

Vital sign measurements included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). Vital signs were graded according to NCI-CTCAE version 4.0. The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in HR (decrease to <60 beats per minute and increase to >100 beats per minute); increase in SBP from Baseline (>=120 to <140 millimeters of mercury [mmHg] Grade 1; >=140 to <160 mmHg [Grade 2]; >=160 [Grade 3]); increase in DBP from Baseline (>=80 to <90 [Grade 1]; >=90 to <100 [Grade 2]; >=100 mmHg [Grade 3]) and change in temperature from Baseline (increase to >=38 or decrease to <=35 degree Centigrade). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. The data for worst-case post Baseline is presented.

End point type	Primary
----------------	---------

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[50] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[51]	3 ^[52]	2 ^[53]	5 ^[54]
Units: Participants				
HR; decrease to <60 beats per minute	1	1	0	2
HR; increase to >100 beats per minute	0	0	1	1
Temp; decrease to <=35 degree Celsius	0	0	0	1
Temp; increase to >=38 degree Celsius	0	0	0	0
SBP; increase to Grade 1 (120-139 mmHg)	0	0	2	1
SBP; increase to Grade 2 (140-159 mmHg)	0	0	0	1

SBP; increase to Grade 3 (≥ 160 mmHg)	0	1	0	1
DBP; increase to Grade 1 (80-89 mmHg)	0	1	2	3
DBP; increase to Grade 2 (90-99 mmHg)	0	1	0	0
DBP; increase to Grade 3 (≥ 100 mmHg)	0	0	0	1

Notes:

[51] - All Treated Population

[52] - All Treated Population

[53] - All Treated Population

[54] - All Treated Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[55]	14 ^[56]		
Units: Participants				
HR; decrease to <60 beats per minute	0	4		
HR; increase to >100 beats per minute	0	5		
Temp; decrease to ≤ 35 degree Celsius	0	0		
Temp; increase to ≥ 38 degree Celsius	0	4		
SBP; increase to Grade 1 (120-139 mmHg)	2	3		
SBP; increase to Grade 2 (140-159 mmHg)	0	4		
SBP; increase to Grade 3 (≥ 160 mmHg)	2	0		
DBP; increase to Grade 1 (80-89 mmHg)	1	7		
DBP; increase to Grade 2 (90-99 mmHg)	0	1		
DBP; increase to Grade 3 (≥ 100 mmHg)	0	1		

Notes:

[55] - All Treated Population

[56] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with abnormal electrocardiogram (ECG) findings-Parts 1 and 2

End point title	Number of participants with abnormal electrocardiogram (ECG) findings-Parts 1 and 2 ^[57]
-----------------	---

End point description:

A 12-lead ECG was measured using an automated ECG machine after at least 5 minutes of rest for the participant in a semi-recumbent or supine position. Number of participants with abnormal ECG findings at any time post-Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

End point type	Primary
----------------	---------

End point timeframe:

Median of 6.143 weeks of drug exposure

Notes:

[57] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[58]	3 ^[59]	2 ^[60]	5 ^[61]
Units: Participants				
Abnormal-not clinically significant	1	3	1	4
Abnormal-clinically significant	0	0	0	0

Notes:

[58] - All Treated Population

[59] - All Treated Population

[60] - All Treated Population

[61] - All Treated Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[62]	14 ^[63]		
Units: Participants				
Abnormal-not clinically significant	3	4		
Abnormal-clinically significant	0	1		

Notes:

[62] - All Treated Population

[63] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum observed plasma concentration (C_{max}) of GSK2849330-Part 1

End point title	Maximum observed plasma concentration (C _{max}) of GSK2849330-Part 1
-----------------	--

End point description:

The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data is defined as C_{max}. Blood samples were collected at indicated time points. The analysis was performed on pharmacokinetic (PK) parameter population which comprised of all participants from the PK concentration population (participants who received at least one dose of GSK2849330 and for whom at least one post-dose PK sample was obtained and analyzed) for whom valid and valuable PK parameters were derived. 99999 indicates data was not available. The geometric coefficient of variation could not be calculated as a single participant was analyzed at the specified time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[64]	3 ^[65]	2 ^[66]	3 ^[67]
Units: Nanograms per milliliter				
geometric mean (geometric coefficient of variation)				
Nanograms per milliliter	29790.0 (± 99999)	62495.2 (± 34.8)	83845.0 (± 24.1)	233997.8 (± 2.7)

Notes:

[64] - PK Parameter Population

[65] - PK Parameter Population

[66] - PK Parameter Population

[67] - PK Parameter Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[68]	5 ^[69]		
Units: Nanograms per milliliter				
geometric mean (geometric coefficient of variation)				
Nanograms per milliliter	639127.3 (± 45.4)	778470.6 (± 14.5)		

Notes:

[68] - PK Parameter Population

[69] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Cmax of GSK2849330-Part 2

End point title	Cmax of GSK2849330-Part 2 ^[70]
-----------------	---

End point description:

PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose

Notes:

[70] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only GSK2849330 30 mg/kg weekly was analyzed in Part 2.

End point values	GSK2849330 30 mg/kg weekly			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[71]			
Units: Nanograms per milliliter				
geometric mean (geometric coefficient of variation)				

Nanograms per milliliter	()			
--------------------------	-----	--	--	--

Notes:

[71] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Time of occurrence of Cmax (Tmax) for GSK2849330-Part 1

End point title	Time of occurrence of Cmax (Tmax) for GSK2849330-Part 1
-----------------	---

End point description:

The time at which Cmax is observed was determined directly from the raw concentration-time data is defined as Tmax. Blood samples were collected at indicated time points for evaluation of pharmacokinetic parameters.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[72]	3 ^[73]	2 ^[74]	3 ^[75]
Units: Hours				
median (full range (min-max))				
Hours	2.070 (2.070 to 2.070)	2.130 (2.000 to 6.170)	88.035 (6.370 to 169.700)	2.280 (2.130 to 6.000)

Notes:

[72] - PK Parameter Population

[73] - PK Parameter Population

[74] - PK Parameter Population

[75] - PK Parameter Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[76]	5 ^[77]		
Units: Hours				
median (full range (min-max))				
Hours	3.280 (2.300 to 6.230)	2.100 (1.830 to 2.330)		

Notes:

[76] - PK Parameter Population

[77] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Tmax for GSK2849330-Part 2

End point title | Tmax for GSK2849330-Part 2^[78]

End point description:

PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2.

End point type | Secondary

End point timeframe:

Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose

Notes:

[78] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only GSK2849330 30 mg/kg weekly was analyzed in Part 2.

End point values	GSK2849330 30 mg/kg weekly			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[79]			
Units: Hours				
median (full range (min-max))				
Hours	(to)			

Notes:

[79] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the concentration time curve (AUC) to a fixed nominal time (AUC[0 to 168]) and AUC(0 to 336) for GSK2849330-Part 1

End point title | Area under the concentration time curve (AUC) to a fixed nominal time (AUC[0 to 168]) and AUC(0 to 336) for GSK2849330-Part 1

End point description:

The AUC to a fixed nominal time AUC(0-168) and AUC(0-336) were calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Blood samples were collected at indicated time points for determination of PK parameters. 99999 indicates data is not available due to insufficient number of participants. Geometric coefficient of variation could not be calculated as a single participant was analyzed at the specified time point. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles).

End point type | Secondary

End point timeframe:

Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[80]	3 ^[81]	2 ^[82]	3 ^[83]
Units: Hours*nanogram per milliliter				
geometric mean (geometric coefficient of variation)				
AUC(0 to 168); n=1, 3, 2, 3, 3, 5	1962762.0 (± 99999)	5787797.8 (± 27.2)	618552.6 (± 20559.2)	18185733.6 (± 28.8)
AUC(0 to 336); 0, 3, 0, 3, 3, 0	99999 (± 99999)	7855808.8 (± 28.7)	99999 (± 99999)	23409694.6 (± 39.4)

Notes:

[80] - PK Parameter Population

[81] - PK Parameter Population

[82] - PK Parameter Population

[83] - PK Parameter Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[84]	5 ^[85]		
Units: Hours*nanogram per milliliter				
geometric mean (geometric coefficient of variation)				
AUC(0 to 168); n=1, 3, 2, 3, 3, 5	54346531.5 (± 30.2)	54388333.7 (± 22.6)		
AUC(0 to 336); 0, 3, 0, 3, 3, 0	72404738.6 (± 34.2)	99999 (± 99999)		

Notes:

[84] - PK Parameter Population

[85] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: AUC(0 to 168) and AUC(0 to 336) for GSK2849330-Part 2

End point title	AUC(0 to 168) and AUC(0 to 336) for GSK2849330-Part 2 ^[86]
-----------------	---

End point description:

PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose

Notes:

[86] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only GSK2849330 30 mg/kg weekly was analyzed in Part 2.

End point values	GSK2849330 30 mg/kg weekly			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[87]			
Units: Hours*nanogram per milliliter				
geometric mean (geometric coefficient of variation)				
Hours*nanogram per milliliter	()			

Notes:

[87] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Serum HER3 from tumor tissue-Parts 1 and 2

End point title	Serum HER3 from tumor tissue-Parts 1 and 2
-----------------	--

End point description:

Pre-treatment and on-treatment biopsy tissues (tumor and normal skin) were analyzed for markers of HER3 pathway such as HER3 that may indicate a pharmacodynamic (PD) response to GSK2849330. Serum HER3 (soluble HER3) analyses was performed. The analysis was performed on PD population which comprised of all participants who received at least one dose of GSK2849330 and for whom at least one evaluable paired pre-treatment PD sample and on-treatment PD sample were obtained and analyzed. Mean and standard deviation for serum HER3 is presented. 99999 indicates data was not available due to insufficient number of participants. Standard deviation could not be calculated as a single participant was analyzed at the specified time points. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

End point type	Secondary
----------------	-----------

End point timeframe:

Median of 6.143 weeks of drug exposure

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[88]	3 ^[89]	1 ^[90]	5 ^[91]
Units: Nanomoles				
arithmetic mean (standard deviation)				
Day 1; pre-dose; n=1, 3, 1, 5, 4, 12	13.65 (± 99999)	17.11 (± 2.603)	16.66 (± 99999)	14.42 (± 4.004)
Day 1; 1 hour; n=1, 3, 1, 5, 4, 11	11.12 (± 99999)	13.14 (± 2.966)	7.53 (± 99999)	10.76 (± 2.228)
Day 1; 6 hours; n=1, 3, 1, 5, 4, 10	9.88 (± 99999)	13.71 (± 2.679)	12.99 (± 99999)	11.69 (± 4.058)
Day 2; n=0, 0, 1, 1, 1, 2	99999 (± 99999)	99999 (± 99999)	8.12 (± 99999)	13.15 (± 99999)
Day 8; n=1, 3, 1, 5, 4, 11	10.14 (± 99999)	11.59 (± 4.353)	10.87 (± 99999)	10.85 (± 3.771)
Day 15; n=0, 2, 1, 3, 4, 10	99999 (± 99999)	10.62 (± 1.110)	7.37 (± 99999)	11.38 (± 3.535)
Day 29; n=1, 3, 1, 4, 4, 8	10.99 (± 99999)	12.18 (± 3.695)	7.69 (± 99999)	6.60 (± 3.220)
Follow-up; n=1, 2, 1, 3, 2, 5	6.19 (± 99999)	9.22 (± 3.090)	14.86 (± 99999)	5.41 (± 1.406)

Notes:

- [88] - PD Population
- [89] - PD Population
- [90] - PD Population
- [91] - PD Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[92]	12 ^[93]		
Units: Nanomoles				
arithmetic mean (standard deviation)				
Day 1; pre-dose; n=1, 3, 1, 5, 4, 12	13.67 (± 4.681)	11.08 (± 5.322)		
Day 1; 1 hour; n=1, 3, 1, 5, 4, 11	9.55 (± 4.437)	5.59 (± 2.709)		
Day 1; 6 hours; n=1, 3, 1, 5, 4, 10	9.39 (± 4.586)	5.35 (± 2.031)		
Day 2; n=0, 0, 1, 1, 1, 2	4.59 (± 99999)	3.50 (± 2.001)		
Day 8; n=1, 3, 1, 5, 4, 11	6.32 (± 2.702)	6.05 (± 2.382)		
Day 15; n=0, 2, 1, 3, 4, 10	9.84 (± 3.127)	4.66 (± 1.402)		
Day 29; n=1, 3, 1, 4, 4, 8	6.91 (± 4.621)	4.13 (± 1.815)		
Follow-up; n=1, 2, 1, 3, 2, 5	3.73 (± 0.424)	4.39 (± 2.975)		

Notes:

- [92] - PD Population
- [93] - PD Population

Statistical analyses

No statistical analyses for this end point

Secondary: Overall response rate (ORR)-Parts 1 and 2

End point title	Overall response rate (ORR)-Parts 1 and 2
End point description:	ORR was determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). ORR was calculated as the number of participants with best overall response of complete response (CR) and partial response (PR). CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 millimeter (mm) in the short axis and PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters (e.g., percent change from Baseline). An estimate to the true response rate for the number of participants analyzed is given. The 95% confidence interval was the exact confidence interval based on binomial proportion for ORR. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
End point type	Secondary
End point timeframe:	Median of 6.143 weeks of drug exposure

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[94]	3 ^[95]	2 ^[96]	5 ^[97]
Units: Participants				
number (confidence interval 95%)				

Participants	0 (0.0 to 97.5)	0 (0.0 to 70.8)	0 (0.0 to 84.2)	0 (0.0 to 52.2)
--------------	-----------------	-----------------	-----------------	-----------------

Notes:

[94] - All Treated Population

[95] - All Treated Population

[96] - All Treated Population

[97] - All Treated Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[98]	14 ^[99]		
Units: Participants				
number (confidence interval 95%)				
Participants	0 (0.0 to 60.2)	1 (0.2 to 33.9)		

Notes:

[98] - All Treated Population

[99] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with antibodies to GSK2849330 in serum

End point title	Number of participants with antibodies to GSK2849330 in serum
-----------------	---

End point description:

Serum samples were collected for the determination of anti-GSK2849330 antibodies using a validated immunoelectrochemiluminescent (ECL) assay. The assay involved screening, confirmation and titration steps (tiered-testing approach). If serum samples contained anti-GSK2849330 antibodies, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants who tested positive for anti-GSK2849330 antibody in confirmatory testing on Day 1 and at any time post-Baseline is presented. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

End point type	Secondary
----------------	-----------

End point timeframe:

Median of 6.143 weeks of drug exposure

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[100]	3 ^[101]	2 ^[102]	5 ^[103]
Units: Participants				
Day1; n=1, 3, 2, 5, 4, 13	0	0	0	0
Any time post-Baseline; n=1, 3, 1, 5, 4, 7	0	0	0	0

Notes:

[100] - All Treated Population

[101] - All Treated Population

[102] - All Treated Population

[103] - All Treated Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[104]	14 ^[105]		
Units: Participants				
Day1; n=1, 3, 2, 5, 4, 13	0	1		
Any time post-Baseline; n=1, 3, 1, 5, 4, 7	0	0		

Notes:

[104] - All Treated Population

[105] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of cluster of differentiation (CD) marker

End point title	Percentage of cluster of differentiation (CD) marker
End point description:	
<p>Blood samples were collected on Day (D) 1 at pre-dose (pre) and at 1 hour (h) and 6 h post infusion for the analysis of markers to evaluate biological activity of GSK2849330. A pre-dose blood sample was collected on D8, D15 and D29 with additional blood sample collected at progression of disease. CDX241 represent CD45+CD3-CD56+CD16+CD69+CD107+, CDX243=CD45+CD3-CD56+CD16+CD69+CD107-; CDX244=CD45+CD3-CD56+CD16+CD69-CD107+ and CDX245=CD45+CD3-CD56+CD16+CD69-CD107-. For participants in GSK2849330 3 mg/kg weekly arm, two samples (S1 and S2) were collected for D15 analysis. 99999 indicates data was not available due to insufficient participants. Standard deviation could not be calculated as a single participant was analyzed at the specified time point. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.</p>	
End point type	Secondary
End point timeframe:	
Median of 6.143 weeks of drug exposure	

End point values	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly	GSK2849330 10 mg/kg every 2 weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[106]	3 ^[107]	1 ^[108]	5 ^[109]
Units: Percentage of CD marker cells				
arithmetic mean (standard deviation)				
CD45+; D1; pre; n=1, 3, 1, 5, 4, 9	99.80 (± 99999)	99.83 (± 0.058)	99.90 (± 99999)	99.76 (± 0.434)
CD45+; D1; 1 h; n=1, 3, 1, 5, 4, 9	99.60 (± 99999)	99.87 (± 0.058)	99.80 (± 99999)	99.76 (± 0.434)
CD45+; D1; 6 h; n=1, 3, 1, 5, 4, 11	99.80 (± 99999)	99.83 (± 0.058)	99.90 (± 99999)	99.8 (± 0.255)
CD45+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	99.10 (± 99999)	99.7 (± 0.424)

CD45+; D8; n=1, 3, 0, 5, 4, 8	100.00 (± 99999)	99.87 (± 0.058)	99999 (± 99999)	99.4 (± 1.231)
CD45+; D15; S1; n=1, 3, 1, 5, 4, 9	99.80 (± 99999)	99.90 (± 0.000)	99.9 (± 99999)	99.78 (± 0.327)
CD45+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	99.8 (± 99999)	99999 (± 99999)
CD45+; D29; n=1, 3, 1, 4, 4, 8	99.90 (± 99999)	99.93 (± 0.058)	100.00 (± 99999)	99.78 (± 0.222)
CD45+; follow-up (FU); n=1, 2, 0, 3, 1, 4	100.00 (± 99999)	99.85 (± 0.071)	99999 (± 99999)	99.63 (± 0.551)
CD45+; unscheduled (USC); n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	100.00 (± 99999)	99999 (± 99999)
CD45+CD3+; D1; pre;n=1, 3, 1, 5, 4, 9	62.70 (± 99999)	69.00 (± 13.313)	58.80 (± 99999)	86.88 (± 2.580)
CD45+CD3+; D1; 1 h; n=1, 3, 1, 5, 4, 9	76.20 (± 99999)	73.83 (± 9.646)	57.30 (± 99999)	87.08 (± 2.153)
CD45+CD3+; D1; 6 h; n=1, 3, 1, 5, 4, 11	81.20 (± 99999)	72.43 (± 12.784)	62.70 (± 99999)	86.88 (± 2.580)
CD45+CD3+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	48.40 (± 99999)	86.60 (± 0.566)
CD45+CD3+; D8; n=1, 3, 0, 5, 4, 8	72.30 (± 99999)	69.67 (± 17.310)	99999 (± 99999)	86.30 (± 1.505)
CD45+CD3+; D15; S1; n=1, 3, 1, 5, 4, 9	73.60 (± 99999)	68.97 (± 19.410)	36.8 (± 99999)	87.52 (± 1.359)
CD45+CD3+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	48.9 (± 99999)	99999 (± 99999)
CD45+CD3+; D29; n=1, 3, 1, 4, 4, 8	76.70 (± 99999)	69.97 (± 17.609)	36.20 (± 99999)	87.30 (± 1.753)
CD45+CD3+; FU; n=1, 2, 0, 3, 1, 4	64.50 (± 99999)	77.15 (± 7.425)	99999 (± 99999)	83.53 (± 7.966)
CD45+CD3+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	58.70 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+; D1; pre;n=1, 3, 1, 5, 4, 9	9.60 (± 99999)	21.67 (± 6.929)	21.60 (± 99999)	35.14 (± 22.721)
CD45+CD3+CD8+; D1; 1 h; n=1, 3, 1, 5, 4, 9	8.00 (± 99999)	20.20 (± 3.538)	20.50 (± 99999)	31.24 (± 21.617)
CD45+CD3+CD8+; D1; 6 h; n=1, 3, 1, 5, 4, 11	8.20 (± 99999)	17.47 (± 2.548)	23.20 (± 99999)	30.82 (± 22.379)
CD45+CD3+CD8+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	21.20 (± 99999)	19.70 (± 7.071)
CD45+CD3+CD8+; D8; n=1, 3, 0, 5, 4, 8	10.50 (± 99999)	22.70 (± 4.987)	99999 (± 99999)	35.24 (± 22.320)
CD45+CD3+CD8+; D15; S1; n=1, 3, 1, 5, 4, 9	9.70 (± 99999)	20.90 (± 6.843)	13 (± 99999)	36.46 (± 22.405)
CD45+CD3+CD8+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	15.7 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+; D29; n=1, 3, 1, 4, 4, 8	11.10 (± 99999)	20.93 (± 6.110)	17.10 (± 99999)	40.85 (± 23.034)
CD45+CD3+CD8+; FU; n=1, 2, 0, 3, 1, 4	7.90 (± 99999)	24.55 (± 4.455)	99999 (± 99999)	45.10 (± 29.487)
CD45+CD3+CD8+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	21.00 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-; D1; pre n=1, 3, 1, 5, 4, 9	50.90 (± 99999)	45.90 (± 9.124)	36.20 (± 99999)	50.76 (± 20.204)
CD45+CD3+CD8-; D1; 1 h; n=1, 3, 1, 5, 4, 9	66.60 (± 99999)	52.77 (± 8.732)	36.50 (± 99999)	54.92 (± 19.213)
CD45+CD3+CD8-; D1; 6 h; n=1, 3, 1, 5, 4, 11	72.00 (± 99999)	54.10 (± 13.421)	36.40 (± 99999)	55.26 (± 19.752)
CD45+CD3+CD8-; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	26.90 (± 99999)	66.35 (± 7.425)
CD45+CD3+CD8-; D8; n=1, 3, 0, 5, 4, 8	63.00 (± 99999)	46.80 (± 12.759)	99999 (± 99999)	50.48 (± 21.133)

CD45+CD3+CD8-; D15; S1; n=1, 3, 1, 5, 4, 9	63.20 (± 99999)	48.37 (± 12.659)	24.3 (± 99999)	50.56 (± 21.357)
CD45+CD3+CD8-; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	36.1 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-; D29; n=1, 3, 1, 4, 4, 8	65.40 (± 99999)	49.10 (± 12.137)	19.90 (± 99999)	45.55 (± 21.821)
CD45+CD3+CD8-; FU; n=1, 2, 0, 3, 1, 4	56.40 (± 99999)	52.50 (± 3.394)	99999 (± 99999)	38.20 (± 21.565)
CD45+CD3+CD8-; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	38.30 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+; D1; pre n=1, 3, 1, 5, 4, 9	24.3 (± 99999)	14.50 (± 7.375)	25.20 (± 99999)	4.96 (± 1.757)
CD45+CD3-CD16+; D1; 1 h; n=1, 3, 1, 5, 4, 9	9.40 (± 99999)	9.03 (± 5.972)	32.50 (± 99999)	4.44 (± 2.411)
CD45+CD3-CD16+; D1; 6 h; n=1, 3, 1, 5, 4, 11	3.10 (± 99999)	5.80 (± 6.538)	23.80 (± 99999)	3.30 (± 2.314)
CD45+CD3-CD16+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	35.30 (± 99999)	2.50 (± 0.566)
CD45+CD3-CD16+; D8; n=1, 3, 0, 5, 4, 8	11.30 (± 99999)	14.71 (± 12.293)	99999 (± 99999)	5.62 (± 3.128)
CD45+CD3-CD16+; D15; S1; n=1, 3, 1, 5, 4, 9	11.40 (± 99999)	13.73 (± 11.816)	47.7 (± 99999)	4.54 (± 3.138)
CD45+CD3-CD16+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	7.6 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+; D29; n=1, 3, 1, 4, 4, 8	11.30 (± 99999)	11.83 (± 9.530)	37.10 (± 99999)	5.75 (± 2.654)
CD45+CD3-CD16+; FU; n=1, 2, 0, 3, 1, 4	20.80 (± 99999)	6.65 (± 4.031)	99999 (± 99999)	6.67 (± 2.237)
CD45+CD3-CD16+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	19.50 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+; D1; pre; n=1, 3, 1, 5, 4, 9	25.70 (± 99999)	14.03 (± 5.636)	25.80 (± 99999)	5.88 (± 1.221)
CD45+CD3-CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9	10.80 (± 99999)	10.13 (± 4.562)	32.80 (± 99999)	5.30 (± 1.581)
CD45+CD3-CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11	4.20 (± 99999)	7.47 (± 5.934)	26.60 (± 99999)	4.70 (± 1.913)
CD45+CD3-CD56+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	42.40 (± 99999)	4.10 (± 0.141)
CD45+CD3-CD56+; D8; n=1, 3, 0, 5, 4, 8	13.70 (± 99999)	14.43 (± 10.625)	99999 (± 99999)	6.16 (± 2.574)
CD45+CD3-CD56+; D15; S1; n=1, 3, 1, 5, 4, 9	13.50 (± 99999)	13.53 (± 11.288)	50.2 (± 99999)	5.96 (± 2.266)
CD45+CD3-CD56+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	8.7 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+; D29; n=1, 3, 1, 4, 4, 8	13.10 (± 99999)	11.90 (± 8.502)	42.30 (± 99999)	6.18 (± 2.428)
CD45+CD3-CD56+; FU; n=1, 2, 0, 3, 1, 4	22.00 (± 99999)	7.80 (± 1.556)	99999 (± 99999)	8.37 (± 3.493)
CD45+CD3-CD56+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	22.10 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+; D1; pre; n=1, 3, 1, 5, 4, 9	3.30 (± 99999)	10.17 (± 8.905)	2.70 (± 99999)	13.18 (± 10.303)
CD45+CD3+CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9	1.80 (± 99999)	8.03 (± 8.410)	1.70 (± 99999)	10.70 (± 7.601)
CD45+CD3+CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11	1.10 (± 99999)	6.87 (± 7.566)	13.80 (± 99999)	12.50 (± 11.924)
CD45+CD3+CD56+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	3.50 (± 99999)	20.90 (± 14.001)
CD45+CD3+CD56+; D8; n=1, 3, 0, 5, 4, 8	3.40 (± 99999)	10.23 (± 8.977)	99999 (± 99999)	12.36 (± 8.813)
CD45+CD3+CD56+; D15; S1; n=1, 3, 1, 5, 4, 9	2.20 (± 99999)	8.40 (± 8.118)	1.30 (± 99999)	13.48 (± 12.640)

CD45+CD3+CD56+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	1.3 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+; D29; n=1, 3, 1, 4, 4, 8	2.80 (± 99999)	9.33 (± 8.629)	3.80 (± 99999)	8.88 (± 5.197)
CD45+CD3+CD56+; FU; n=1, 2, 0, 3, 1, 4	2.50 (± 99999)	16.20 (± 13.294)	99999 (± 99999)	16.07 (± 6.757)
CD45+CD3+CD56+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	1.60 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD56+; D1; pre; n=1, 3, 1, 5, 4, 9	23.40 (± 99999)	12.23 (± 6.307)	23.30 (± 99999)	4.48 (± 1.638)
CD45+CD3-CD16+CD56+; D1;1 h; n=1, 3, 1, 5, 4, 9	9.10 (± 99999)	8.10 (± 5.237)	31.10 (± 99999)	3.98 (± 2.244)
CD45+CD3-CD16+CD56+; D1;6 h; n=1,3,1,5,4,11	3.00 (± 99999)	4.90 (± 5.403)	19.70 (± 99999)	2.92 (± 2.348)
CD45+CD3-CD16+CD56+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	33.60 (± 99999)	2.40 (± 0.566)
CD45+CD3-CD16+CD56+; D8; n=1, 3, 0, 5, 4, 8	10.80 (± 99999)	12.33 (± 10.979)	99999 (± 99999)	5.00 (± 2.891)
CD45+CD3-CD16+CD56+; D15; S1; n=1, 3, 1, 5, 4, 9	10.90 (± 99999)	11.93 (± 11.007)	43.5 (± 99999)	4.14 (± 2.926)
CD45+CD3-CD16+CD56+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	5.4 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD56+; D29; n=1, 3, 1, 4, 4, 8	10.80 (± 99999)	10.20 (± 8.542)	32.90 (± 99999)	5.05 (± 2.357)
CD45+CD3-CD16+CD56+; FU; n=1, 2, 0, 3, 1, 4	19.30 (± 99999)	5.50 (± 3.111)	99999 (± 99999)	6.07 (± 2.566)
CD45+CD3-CD16+CD56+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	18.30 (± 99999)	99999 (± 99999)
CD45+CD3-CD19+; D1; pre n=1, 3, 1, 5, 4, 9	9.10 (± 99999)	12.67 (± 4.936)	12.30 (± 99999)	5.36 (± 3.364)
CD45+CD3-CD19+; D1;1 h; n=1, 3, 1, 5, 4, 9	11.70 (± 99999)	13.77 (± 3.323)	8.30 (± 99999)	6.04 (± 3.492)
CD45+CD3-CD19+; D1;6 h; n=1,3,1,5,4,11	11.30 (± 99999)	16.23 (± 3.329)	6.00 (± 99999)	6.36 (± 3.817)
CD45+CD3-CD19+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	6.40 (± 99999)	8.10 (± 0.141)
CD45+CD3-CD19+; D8; n=1, 3, 0, 5, 4, 8	10.70 (± 99999)	12.77 (± 4.701)	99999 (± 99999)	5.76 (± 3.895)
CD45+CD3-CD19+; D15; S1; n=1, 3, 1, 5, 4, 9	10.60 (± 99999)	14.03 (± 6.116)	7.9 (± 99999)	5.10 (± 3.180)
CD45+CD3-CD19+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	26.2 (± 99999)	99999 (± 99999)
CD45+CD3-CD19+; D29; n=1, 3, 1, 4, 4, 8	8.90 (± 99999)	15.37 (± 7.392)	13.70 (± 99999)	5.10 (± 3.995)
CD45+CD3-CD19+; FU; n=1, 2, 0, 3, 1, 4	10.00 (± 99999)	12.05 (± 4.313)	99999 (± 99999)	6.17 (± 8.361)
CD45+CD3-CD19+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	15.90 (± 99999)	99999 (± 99999)
CD45+CD14+; D1; pre; n=1, 3, 1, 5, 4, 9	5.80 (± 99999)	4.87 (± 0.971)	10.40 (± 99999)	6.58 (± 1.293)
CD45+CD14+; D1;1 h; n=1, 3, 1, 5, 4, 9	1.40 (± 99999)	3.63 (± 2.103)	11.30 (± 99999)	5.20 (± 1.461)
CD45+CD14+; D1;6 h; n=1,3,1,5,4,11	4.50 (± 99999)	5.37 (± 2.804)	11.80 (± 99999)	6.24 (± 1.756)
CD45+CD14+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	5.30 (± 99999)	5.10 (± 2.828)
CD45+CD14+; D8; n=1, 3, 0, 5, 4, 8	7.30 (± 99999)	6.30 (± 0.872)	99999 (± 99999)	6.60 (± 1.594)
CD45+CD14+; D15; S1; n=1, 3, 1, 5, 4, 9	4.70 (± 99999)	5.60 (± 1.652)	5.9 (± 99999)	6.66 (± 1.108)
CD45+CD14+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	18.9 (± 99999)	99999 (± 99999)

CD45+CD14+; D29; n=1, 3, 1, 4, 4, 8	5.00 (± 99999)	4.93 (± 0.231)	7.60 (± 99999)	5.53 (± 1.162)
CD45+CD14+; FU; n=1, 2, 0, 3, 1, 4	7.50 (± 99999)	5.50 (± 1.273)	99999 (± 99999)	8.03 (± 0.862)
CD45+CD14+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	8.50 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD69+; D1; pre; n=1, 3, 1, 5, 4, 9	67.92 (± 99999)	80.37 (± 3.710)	83.47 (± 99999)	80.92 (± 7.038)
CD45+CD3-CD16+CD69+; D1;1 h; n=1, 3, 1, 5, 4, 9	76.94 (± 99999)	79.76 (± 2.213)	87.72 (± 99999)	81.88 (± 8.557)
CD45+CD3-CD16+CD69+; D1;6 h; n=1,3,1,5,4,11	77.72 (± 99999)	76.99 (± 12.536)	90.79 (± 99999)	84.25 (± 5.802)
CD45+CD3-CD16+CD69+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	91.00 (± 99999)	89.03 (± 3.776)
CD45+CD3-CD16+CD69+; D8; n=1, 3, 0, 5, 4, 8	77.29 (± 99999)	75.83 (± 5.870)	99999 (± 99999)	81.34 (± 10.373)
CD45+CD3-CD16+CD69+; D15;S1; n=1, 3, 1, 5, 4, 9	81.61 (± 99999)	79.04 (± 3.286)	96.49 (± 99999)	80.28 (± 6.867)
CD45+CD3-CD16+CD69+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	92.76 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD69+; D29; n=1, 3, 1, 4, 4, 8	79.28 (± 99999)	81.92 (± 2.273)	85.01 (± 99999)	80.73 (± 6.688)
CD45+CD3-CD16+CD69+; FU; n=1, 2, 0, 3, 1, 4	77.38 (± 99999)	84.40 (± 1.506)	99999 (± 99999)	81.52 (± 12.737)
CD45+CD3-CD16+CD69+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	64.88 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD107+; D1; pre; n=1, 3, 1, 5, 4, 9	7.06 (± 99999)	13.40 (± 5.851)	18.18 (± 99999)	19.27 (± 13.221)
CD45+CD3-CD16+CD107+; D1;1 h; n=1, 3, 1, 5,4,9	12.19 (± 99999)	15.18 (± 8.160)	8.77 (± 99999)	21.43 (± 13.416)
CD45+CD3-CD16+CD107+; D1;6 h; n=1,3,1,5,4,11	14.85 (± 99999)	15.30 (± 6.477)	40.79 (± 99999)	32.01 (± 16.156)
CD45+CD3-CD16+CD107+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99999 (± 99999)	26.00 (± 99999)	31.96 (± 9.454)
CD45+CD3-CD16+CD107+; D8; n=1, 3, 0, 5, 4, 8	33.73 (± 99999)	6.90 (± 3.044)	99999 (± 99999)	22.42 (± 10.572)
CD45+CD3-CD16+CD107+; D15; S1; n=1, 3, 1, 5, 4, 9	17.29 (± 99999)	7.72 (± 4.937)	38.6 (± 99999)	17.00 (± 8.663)
CD45+CD3-CD16+CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	65.89 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD107+; D29; n=1, 3, 1, 4, 4, 8	16.94 (± 99999)	8.78 (± 3.719)	52.86 (± 99999)	19.08 (± 4.869)
CD45+CD3-CD16+CD107+; FU; n=1, 2, 0, 3, 1, 4	14.38 (± 99999)	22.49 (± 13.902)	99999 (± 99999)	31.28 (± 29.410)
CD45+CD3-CD16+CD107+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	16.51 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD69+CD107+; D1; pre; n=1,3,1,5,4,9	6.86 (± 99999)	13.33 (± 5.869)	18.18 (± 99999)	19.05 (± 12.990)
CD45+CD3-CD16+CD69+CD107+; D1;1 h;n=1,3,1,5,4,9	11.81 (± 99999)	14.86 (± 7.795)	8.77 (± 99999)	21.29 (± 13.208)
CD45+CD3-CD16+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11	14.85 (± 99999)	15.29 (± 6.364)	38.16 (± 99999)	31.96 (± 16.199)
CD45+CD3-CD16+CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	26.00 (± 99999)	31.42 (± 10.218)
CD45+CD3-CD16+CD69+CD107+; D8; n=1,3,0,5,4,8	32.80 (± 99999)	6.77 (± 3.013)	99999 (± 99999)	22.35 (± 10.534)
CD45+CD3-CD16+CD69+CD107+; D15; S1;n=1,3,1,5,4,9	16.92 (± 99999)	7.60 (± 4.890)	38.6 (± 99999)	16.94 (± 8.669)
CD45+CD3-CD16+CD69+CD107+; D15; S2;n=0,0,1,0,0, 0	99999 (± 99999)	99999 (± 99999)	64.8 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD69+CD107+; D29; n=1,3,1,4,4,8	16.42 (± 99999)	8.70 (± 3.598)	50.41 (± 99999)	18.76 (± 4.922)

CD45+CD3-CD16+CD69+CD107+; FU; n=1,2,0,3,1,4	14.34 (± 99999)	22.24 (± 13.548)	99999 (± 99999)	31.06 (± 29.550)
CD45+CD3-CD16+CD69+CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	15.77 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD69+CD107-; D1;pre; n=1,3,1,5,4,9	61.07 (± 99999)	67.04 (± 7.996)	65.29 (± 99999)	61.87 (± 9.438)
CD45+CD3-CD16+CD69+CD107-; D1;1 h;n=1,3,1,5,4,9	65.12 (± 99999)	64.90 (± 8.250)	78.95 (± 99999)	60.59 (± 8.489)
CD45+CD3-CD16+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11	62.87 (± 99999)	61.71 (± 10.282)	52.63 (± 99999)	52.29 (± 11.006)
CD45+CD3-CD16+CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	65.00 (± 99999)	57.62 (± 13.987)
CD45+CD3-CD16+CD69+CD107-; D8; n=1,3,0,5,4,8	44.49 (± 99999)	69.06 (± 8.555)	99999 (± 99999)	58.99 (± 8.379)
CD45+CD3-CD16+CD69+CD107-; D15;S1; n=1,3,1,5,4,9	64.68 (± 99999)	71.45 (± 1.611)	57.89 (± 99999)	63.34 (± 4.338)
CD45+CD3-CD16+CD69+CD107-; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	27.96 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD69+CD107-; D29; n=1,3,1,4,4,8	62.87 (± 99999)	73.22 (± 4.103)	34.60 (± 99999)	61.98 (± 6.511)
CD45+CD3-CD16+CD69+CD107-; FU; n=1,2,0,3,1,4	63.04 (± 99999)	62.16 (± 15.047)	99999 (± 99999)	50.46 (± 18.585)
CD45+CD3-CD16+CD69+CD107-; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	49.11 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD69-CD107+; D1;pre n=1,3,1,5,4,9	0.21 (± 99999)	0.07 (± 0.115)	0.00 (± 99999)	0.22 (± 0.265)
CD45+CD3-CD16+CD69-CD107+; D1;1 h;n=1,3,1,5,4,9	0.38 (± 99999)	0.31 (± 0.399)	0.00 (± 99999)	0.14 (± 0.238)
CD45+CD3-CD16+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11	0.00 (± 99999)	0.09 (± 0.162)	2.63 (± 99999)	0.05 (± 0.069)
CD45+CD3-CD16+CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	0.00 (± 99999)	0.54 (± 0.764)
CD45+CD3-CD16+CD69-CD107+; D8; n=1,3,0,5,4,8	0.94 (± 99999)	0.14 (± 0.029)	99999 (± 99999)	0.07 (± 0.100)
CD45+CD3-CD16+CD69-CD107+; D15;S1; n=1,3,1,5,4,9	0.37 (± 99999)	0.12 (± 0.102)	0.00 (± 99999)	0.05 (± 0.121)
CD45+CD3-CD16+CD69-CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	1.09 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD69-CD107+; D29; n=1,3,1,4,4,8	0.52 (± 99999)	0.07 (± 0.127)	2.45 (± 99999)	0.32 (± 0.326)
CD45+CD3-CD16+CD69-CD107+; FU; n=1,2,0,3,1,4	0.03 (± 99999)	0.26 (± 0.361)	99999 (± 99999)	0.22 (± 0.333)
CD45+CD3-CD16+CD69-CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	0.74 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD69-CD107-; D1;pre; n=1,3,1,5,4,9	31.87 (± 99999)	19.57 (± 3.611)	16.53 (± 99999)	18.86 (± 7.256)
CD45+CD3-CD16+CD69-CD107-; D1;1 h;n=1,3,1,5,4,9	22.68 (± 99999)	19.93 (± 2.396)	12.28 (± 99999)	17.98 (± 8.736)
CD45+CD3-CD16+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11	22.28 (± 99999)	22.91 (± 12.511)	6.58 (± 99999)	15.70 (± 5.783)
CD45+CD3-CD16+CD69-CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	9.00 (± 99999)	10.43 (± 4.540)
CD45+CD3-CD16+CD69-CD107-; D8; n=1,3,0,5,4,8	21.78 (± 99999)	24.03 (± 5.842)	99999 (± 99999)	18.63 (± 10.331)
CD45+CD3-CD16+CD69-CD107-; D15; S1;n=1,3,1,5,4,9	18.03 (± 99999)	20.84 (± 3.338)	3.51 (± 99999)	19.67 (± 6.810)
CD45+CD3-CD16+CD69-CD107-; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	6.15 (± 99999)	99999 (± 99999)
CD45+CD3-CD16+CD69-CD107-; D29; n=1,3,1,4,4,8	20.20 (± 99999)	18.00 (± 2.247)	12.53 (± 99999)	18.97 (± 6.747)
CD45+CD3-CD16+CD69-CD107-; FU; n=1,2,0,3,1,4	22.59 (± 99999)	15.35 (± 1.146)	99999 (± 99999)	18.34 (± 12.586)

CD45+CD3-CD16+CD69-CD107-; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	34.38 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD69+; D1;pre; n=1,3,1,5,4,9	67.22 (± 99999)	78.33 (± 3.952)	82.26 (± 99999)	77.55 (± 7.943)
CD45+CD3-CD56+CD69+; D1;1 h;n=1,3,1,5,4,9	75.33 (± 99999)	77.13 (± 4.906)	86.96 (± 99999)	79.21 (± 8.936)
CD45+CD3-CD56+CD69+;D1;6 h;n=1,3,1,5,4,11	79.56 (± 99999)	74.82 (± 11.935)	92.92 (± 99999)	80.05 (± 5.668)
CD45+CD3-CD56+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	87.50 (± 99999)	84.69 (± 5.862)
CD45+CD3-CD56+CD69+; D8; n=1,3,0,5,4,8	75.33 (± 99999)	72.08 (± 3.948)	99999 (± 99999)	77.49 (± 9.757)
CD45+CD3-CD56+CD69+; D15;S1; n=1,3,1,5,4,9	80.07 (± 99999)	76.83 (± 2.746)	93.33 (± 99999)	76.69 (± 5.772)
CD45+CD3-CD56+CD69+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	90.79 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD69+; D29; n=1,3,1,4,4,8	76.99 (± 99999)	80.41 (± 3.445)	83.53 (± 99999)	77.90 (± 5.693)
CD45+CD3-CD56+CD69+; FU; n=1,2,0,3,1,4	75.72 (± 99999)	83.15 (± 0.643)	99999 (± 99999)	78.85 (± 8.804)
CD45+CD3-CD56+CD69+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	64.59 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD107+; D1; pre; n=1,3,1,5,4,9	2.47 (± 99999)	11.70 (± 5.812)	15.32 (± 99999)	16.30 (± 12.987)
CD45+CD3-CD56+CD107+; D1;1 h;n=1,3,1,5,4,9	5.13 (± 99999)	13.87 (± 7.853)	6.69 (± 99999)	17.11 (± 11.990)
CD45+CD3-CD56+CD107+;D1;6 h;n=1,3,1,5,4,11	14.60 (± 99999)	16.66 (± 7.368)	31.76 (± 99999)	23.41 (± 13.644)
CD45+CD3-CD56+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	21.67 (± 99999)	28.04 (± 7.347)
CD45+CD3-CD56+CD107+; D8; n=1,3,0,5,4,8	32.45 (± 99999)	6.79 (± 2.953)	99999 (± 99999)	17.46 (± 7.730)
CD45+CD3-CD56+CD107+; D15;S1; n=1,3,1,5,4,9	15.54 (± 99999)	6.48 (± 3.558)	39.17 (± 99999)	14.18 (± 7.919)
CD45+CD3-CD56+CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	54.4 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD107+; D29; n=1,3,1,4,4,8	15.85 (± 99999)	7.77 (± 3.841)	48.21 (± 99999)	15.09 (± 1.735)
CD45+CD3-CD56+CD107+; FU; n=1,2,0,3,1,4	13.08 (± 99999)	19.93 (± 11.469)	99999 (± 99999)	26.54 (± 22.053)
CD45+CD3-CD56+CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	16.45 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD69+CD107+; D1; pre n=1,3,1,5,4,9	2.45 (± 99999)	11.58 (± 5.907)	15.32 (± 99999)	15.98 (± 12.746)
CD45+CD3-CD56+CD69+CD107+; D1;1 h;n=1,3,1,5,4,9	4.97 (± 99999)	13.56 (± 7.455)	6.96 (± 99999)	16.90 (± 11.974)
CD45+CD3-CD56+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11	14.60 (± 99999)	15.94 (± 6.586)	31.76 (± 99999)	23.27 (± 13.781)
CD45+CD3-CD56+CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	21.67 (± 99999)	27.36 (± 7.460)
CD45+CD3-CD56+CD69+CD107+; D8; n=1,3,0,5,4,8	31.18 (± 99999)	6.63 (± 2.770)	99999 (± 99999)	17.32 (± 7.645)
CD45+CD3-CD56+CD69+CD107+; D15;S1; n=1,3,1,5,4,9	15.13 (± 99999)	6.40 (± 3.545)	39.17 (± 99999)	14.03 (± 7.922)
CD45+CD3-CD56+CD69+CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	54.27 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD69+CD107+; D29; n=1,3,1,4,4,8	15.34 (± 99999)	7.77 (± 3.841)	46.54 (± 99999)	14.70 (± 1.922)
CD45+CD3-CD56+CD69+CD107+; FU; n=1,2,0,3,1,4	13.01 (± 99999)	19.60 (± 11.130)	99999 (± 99999)	26.27 (± 22.189)
CD45+CD3-CD56+CD69+CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	15.52 (± 99999)	99999 (± 99999)

CD45+CD3-CD56+CD69+CD107-; D1; pre; n=1,3,1,5,4,9	64.78 (± 99999)	66.74 (± 7.360)	66.94 (± 99999)	61.56 (± 9.286)
CD45+CD3-CD56+CD69+CD107-; D1;1 h;n=1,3,1,5,4,9	70.36 (± 99999)	63.58 (± 7.453)	80.00 (± 99999)	62.31 (± 7.582)
CD45+CD3-CD56+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11	64.96 (± 99999)	58.88 (± 10.865)	61.18 (± 99999)	56.78 (± 8.650)
CD45+CD3-CD56+CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	65.83 (± 99999)	57.33 (± 13.329)
CD45+CD3-CD56+CD69+CD107-; D15;S1; n=1,3,1,5,4,9	64.95 (± 99999)	70.43 (± 0.830)	54.17 (± 99999)	62.66 (± 4.313)
CD45+CD3-CD56+CD69+CD107-; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	36.52 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD69+CD107-; D8; n=1,3,0,5,4,8	44.15 (± 99999)	65.44 (± 6.176)	99999 (± 99999)	60.18 (± 8.140)
CD45+CD3-CD56+CD69+CD107-; D29; n=1,3,1,4,4,8	61.65 (± 99999)	72.64 (± 2.420)	36.99 (± 99999)	63.21 (± 4.900)
CD45+CD3-CD56+CD69+CD107-; FU; n=1,2,0,3,1,4	62.71 (± 99999)	63.55 (± 11.780)	99999 (± 99999)	52.58 (± 16.165)
CD45+CD3-CD56+CD69+CD107-; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	49.07 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD69-CD107+; D1; pre; n=1,3,1,5,4,9	0.03 (± 99999)	0.11 (± 0.095)	0.00 (± 99999)	0.31 (± 0.267)
CD45+CD3-CD56+CD69-CD107+; D1;1 h;n=1,3,1,5,4,9	0.17 (± 99999)	0.31 (± 0.412)	0.00 (± 99999)	0.21 (± 0.123)
CD45+CD3-CD56+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11	0.00 (± 99999)	0.72 (± 0.968)	0.00 (± 99999)	0.14 (± 0.226)
CD45+CD3-CD56+CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	0.00 (± 99999)	0.68 (± 0.113)
CD45+CD3-CD56+CD69-CD107+; D8; n=1,3,0,5,4,8	1.27 (± 99999)	0.16 (± 0.182)	99999 (± 99999)	0.14 (± 0.186)
CD45+CD3-CD56+CD69-CD107+; D15;S1; n=1,3,1,5,4,9	0.41 (± 99999)	0.09 (± 0.076)	0 (± 99999)	0.15 (± 0.145)
CD45+CD3-CD56+CD69-CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	0.14 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD69-CD107+; D29; n=1,3,1,4,4,8	0.50 (± 99999)	0.00 (± 0.000)	1.67 (± 99999)	0.39 (± 0.541)
CD45+CD3-CD56+CD69-CD107+; FU; n=1,2,0,3,1,4	0.07 (± 99999)	0.34 (± 0.332)	99999 (± 99999)	0.27 (± 0.379)
CD45+CD3-CD56+CD69-CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	0.93 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD69-CD107-; D1; pre; n=1,3,1,5,4,9	32.75 (± 99999)	21.56 (± 3.938)	17.74 (± 99999)	22.14 (± 8.116)
CD45+CD3-CD56+CD69-CD107-; D1;1 h;n=1,3,1,5,4,9	24.50 (± 99999)	22.55 (± 5.154)	13.04 (± 99999)	20.58 (± 8.921)
CD45+CD3-CD56+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11	20.44 (± 99999)	24.46 (± 11.748)	7.06 (± 99999)	19.81 (± 5.486)
CD45+CD3-CD56+CD69-CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	12.50 (± 99999)	14.64 (± 5.975)
CD45+CD3-CD56+CD69-CD107-; D8; n=1,3,0,5,4,8	23.40 (± 99999)	27.76 (± 3.835)	99999 (± 99999)	22.37 (± 9.797)
CD45+CD3-CD56+CD69-CD107-; D15;S1; n=1,3,1,5,4,9	19.57 (± 99999)	23.09 (± 2.774)	6.67 (± 99999)	23.16 (± 5.735)
CD45+CD3-CD56+CD69-CD107-; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	9.08 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD69-CD107-; D29; n=1,3,1,4,4,8	22.56 (± 99999)	19.59 (± 3.445)	14.80 (± 99999)	21.73 (± 5.751)
CD45+CD3-CD56+CD69-CD107-; FU; n=1,2,0,3,1,4	24.28 (± 99999)	16.52 (± 0.311)	99999 (± 99999)	20.87 (± 8.475)
CD45+CD3-CD56+CD69-CD107-; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	34.48 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD16+CD69+; D1; pre; n=1,3,1,5,4,9	67.96 (± 99999)	79.63 (± 3.253)	83.93 (± 99999)	80.66 (± 7.578)

CD45+CD3-CD56+CD16+CD69+; D1;1 h;n=1,3,1,5,4,9	76.86 (± 99999)	79.33 (± 2.688)	88.07 (± 99999)	81.64 (± 9.116)
CD45+CD3-CD56+CD16+CD69+;D1;6 h;n=1,3,1,5,4,11	78.24 (± 99999)	76.67 (± 11.942)	93.65 (± 99999)	83.35 (± 5.763)
CD45+CD3-CD56+CD16+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	90.53 (± 99999)	89.13 (± 3.147)
CD45+CD3-CD56+CD16+CD69+; D8; n=1,3,0,5,4,8	77.01 (± 99999)	75.37 (± 5.656)	99999 (± 99999)	80.55 (± 10.272)
CD45+CD3-CD56+CD16+CD69+; D15;S1; n=1,3,1,5,4,9	81.53 (± 99999)	78.47 (± 3.127)	97.12 (± 99999)	79.94 (± 6.952)
CD45+CD3-CD56+CD16+CD69+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	94.42 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD16+CD69+; D29; n=1,3,1,4,4,8	78.98 (± 99999)	81.90 (± 2.566)	85.89 (± 99999)	80.16 (± 7.448)
CD45+CD3-CD56+CD16+CD69+; FU; n=1,2,0,3,1,4	77.43 (± 99999)	83.80 (± 1.485)	99999 (± 99999)	81.09 (± 12.356)
CD45+CD3-CD56+CD16+CD69+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	65.35 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD16+CD107+; D1;pre; n=1,3,1,5,4,9	6.82 (± 99999)	12.17 (± 5.660)	16.96 (± 99999)	17.55 (± 13.586)
CD45+CD3-CD56+CD16+CD107+; D1;1 h;n=1,3,1,5,4,9	12.40 (± 99999)	14.37 (± 7.788)	7.34 (± 99999)	19.24 (± 13.929)
CD45+CD3-CD56+CD16+CD107+;D1;6 h;n=1,3,1,5,4,11	15.03 (± 99999)	14.86 (± 7.082)	31.75 (± 99999)	27.52 (± 16.167)
CD45+CD3-CD56+CD16+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	25.26 (± 99999)	32.24 (± 9.970)
CD45+CD3-CD56+CD16+CD107+; D8; n=1,3,0,5,4,8	33.08 (± 99999)	6.53 (± 3.339)	99999 (± 99999)	18.59 (± 9.084)
CD45+CD3-CD56+CD16+CD107+; D15;S1; n=1,3,1,5,4,9	16.23 (± 99999)	6.20 (± 4.025)	40.38 (± 99999)	14.69 (± 8.825)
CD45+CD3-CD56+CD16+CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	60.94 (± 99999)	99999 (± 99999)
CD45+CD3-CD56+CD16+CD107+; D29; n=1,3,1,4,4,8	16.53 (± 99999)	8.01 (± 4.316)	50.92 (± 99999)	15.68 (± 2.613)
CD45+CD3-CD56+CD16+CD107+; FU; n=1,2,0,3,1,4	13.70 (± 99999)	19.58 (± 14.078)	99999 (± 99999)	29.76 (± 28.400)
CD45+CD3-CD56+CD16+CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	16.42 (± 99999)	99999 (± 99999)
CDX241; D1;pre; n=1,3,1,5,4,9	6.63 (± 99999)	12.09 (± 5.664)	16.96 (± 99999)	17.32 (± 13.319)
CDX241; D1;1h;n=1,3,1,5,4,9	12.01 (± 99999)	14.02 (± 7.382)	7.34 (± 99999)	19.15 (± 13.818)
CDX241; D1;6h;n=1,3,1,5,4,11	15.03 (± 99999)	14.75 (± 6.934)	31.75 (± 99999)	27.46 (± 16.219)
CDX241; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	25.26 (± 99999)	31.68 (± 10.769)
CDX241; D8; n=1,3,0,5,4,8	32.10 (± 99999)	6.47 (± 3.238)	99999 (± 99999)	18.50 (± 9.029)
CDX241; D15;S1;n=1,3,1,5,4,9	15.97 (± 99999)	6.13 (± 3.908)	40.38 (± 99999)	14.62 (± 8.827)
CDX241; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	60.94 (± 99999)	99999 (± 99999)
CDX241; D29; n=1,3,1,4,4,8	15.99 (± 99999)	8.01 (± 4.316)	49.39 (± 99999)	15.40 (± 2.640)
CDX241; FU; n=1,2,0,3,1,4	13.66 (± 99999)	19.29 (± 13.668)	99999 (± 99999)	29.58 (± 28.512)
CDX241; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	15.64 (± 99999)	99999 (± 99999)
CDX243; D1; pre; n=1,3,1,5,4,9	61.33 (± 99999)	67.54 (± 8.092)	66.96 (± 99999)	63.34 (± 9.199)
CDX243; D1;1h; n=1,3,1,5,4,9	64.84 (± 99999)	65.31 (± 7.929)	80.73 (± 99999)	62.49 (± 8.086)

CDX243;D1;6h; n=1,3,1,5,4,11	63.21 (± 99999)	61.93 (± 9.710)	61.90 (± 99999)	55.89 (± 11.139)
CDX243; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	65.26 (± 99999)	57.46 (± 13.909)
CDX243; D8; n=1,3,0,5,4,8	44.92 (± 99999)	68.91 (± 8.623)	99999 (± 99999)	62.04 (± 7.093)
CDX243; D15;S1; n=1,3,1,5,4,9	65.55 (± 99999)	72.34 (± 0.958)	56.73 (± 99999)	65.32 (± 4.554)
CDX243; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	33.48 (± 99999)	99999 (± 99999)
CDX243; D29; n=1,3,1,4,4,8	62.99 (± 99999)	73.88 (± 3.073)	36.50 (± 99999)	64.75 (± 5.261)
CDX243; FU;n=1,2,0,3,1,4	63.77 (± 99999)	64.51 (± 15.146)	99999 (± 99999)	51.52 (± 18.071)
CDX243; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	49.72 (± 99999)	99999 (± 99999)
CDX244; D1; pre; n=1,3,1,5,4,9	0.18 (± 99999)	0.08 (± 0.139)	0.00 (± 99999)	0.23 (± 0.289)
CDX244; D1;1h;n=1,3,1,5,4,9	0.39 (± 99999)	0.35 (± 0.454)	0.00 (± 99999)	0.09 (± 0.137)
CDX244; D1;6h;n=1,3,1,5,4,11	0.00 (± 99999)	0.11 (± 0.191)	0.00 (± 99999)	0.06 (± 0.089)
CDX244; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	0.00 (± 99999)	0.57 (± 0.799)
CDX244; D8; n=1,3,0,5,4,8	0.98 (± 99999)	0.06 (± 0.110)	99999 (± 99999)	0.08 (± 0.116)
CDX244; D15;S1;n=1,3,1,5,4,9	0.26 (± 99999)	0.07 (± 0.115)	0.00 (± 99999)	1.53 (± 99999)
CDX244; D15;S2n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	0.00 (± 99999)	99999 (± 99999)
CDX244; D29; n=1,3,1,4,4,8	0.54 (± 99999)	0.00 (± 0.000)	1.53 (± 99999)	0.28 (± 0.392)
CDX244; FU;n=1,2,0,3,1,4	0.04 (± 99999)	0.29 (± 0.410)	99999 (± 99999)	0.18 (± 0.267)
CDX244; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	0.79 (± 99999)	99999 (± 99999)
CDX245; D1; pre; n=1,3,1,5,4,9	31.86 (± 99999)	20.28 (± 3.144)	16.07 (± 99999)	19.11 (± 7.819)
CDX245; D1; 1h; n=1,3,1,5,4,9	22.75 (± 99999)	20.32 (± 2.902)	11.93 (± 99999)	18.27 (± 9.233)
CDX245; D1; 6h; n=1,3,1,5,4,11	21.76 (± 99999)	23.22 (± 11.931)	6.35 (± 99999)	16.59 (± 5.742)
CDX245; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	9.47 (± 99999)	10.31 (± 3.946)
CDX245; D8; n=1,3,0,5,4,8	22.00 (± 99999)	24.56 (± 5.547)	99999 (± 99999)	19.37 (± 10.290)
CDX245; D15; S1; n=1,3,1,5,4,9	18.22 (± 99999)	21.46 (± 3.242)	2.88 (± 99999)	20.00 (± 6.887)
CDX245; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	5.58 (± 99999)	99999 (± 99999)
CDX245; D29; n=1,3,1,4,4,8	20.48 (± 99999)	18.10 (± 2.566)	12.58 (± 99999)	19.57 (± 7.550)
CDX245; FU; n=1,2,0,3,1,4	22.53 (± 99999)	15.91 (± 1.075)	99999 (± 99999)	18.72 (± 12.153)
CDX245; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	33.86 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD69+;D1pre; n=1,3,1,5,4,9	62.80 (± 99999)	77.83 (± 5.748)	84.62 (± 99999)	76.05 (± 13.328)
CD45+CD3+CD56+CD69+;D1;1 h;n=1,3,1,5,4,9	71.21 (± 99999)	77.91 (± 8.757)	100.00 (± 99999)	74.68 (± 12.530)
CD45+CD3+CD56+CD69+;D1;6 h;n=1,3,1,5,4,11	77.14 (± 99999)	76.55 (± 11.000)	100.00 (± 99999)	75.64 (± 10.831)
CD45+CD3+CD56+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	90.00 (± 99999)	79.51 (± 11.823)
CD45+CD3+CD56+CD69+; D8; n=1,3,0,5,4,8	70.35 (± 99999)	79.41 (± 6.359)	99999 (± 99999)	77.26 (± 8.083)

CD45+CD3+CD56+CD69+; D15;S1; n=1,3,1,5,4,9	76.53 (± 99999)	81.26 (± 7.195)	100 (± 99999)	76.72 (± 9.716)
CD45+CD3+CD56+CD69+;D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	90.91 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD69+; D29; n=1,3,1,4,4,8	76.53 (± 99999)	84.46 (± 9.848)	92.11 (± 99999)	75.11 (± 5.695)
CD45+CD3+CD56+CD69+; FU;n=1,2,0,3,1,4	76.95 (± 99999)	83.76 (± 2.977)	99999 (± 99999)	76.93 (± 2.841)
CD45+CD3+CD56+CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	73.08 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD107+;D1pre; n=1,3,1,5,4,9	8.10 (± 99999)	23.44 (± 3.025)	30.77 (± 99999)	24.69 (± 14.219)
CD45+CD3+CD56+CD107+;D1;1 h;n=1,3,1,5,4,9	16.16 (± 99999)	25.59 (± 8.435)	16.67 (± 99999)	25.84 (± 13.782)
CD45+CD3+CD56+CD107+;D1;6 h;n=1,3,1,5,4,11	17.14 (± 99999)	27.55 (± 9.084)	77.27 (± 99999)	25.54 (± 14.785)
CD45+CD3+CD56+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	50.00 (± 99999)	12.40 (± 2.892)
CD45+CD3+CD56+CD107+; D8; n=1,3,0,5,4,8	34.51 (± 99999)	25.08 (± 12.140)	99999 (± 99999)	22.70 (± 6.042)
CD45+CD3+CD56+CD107+; D15; S1;n=1,3,1,5,4,9	24.44 (± 99999)	16.39 (± 9.804)	66.67 (± 99999)	20.15 (± 15.543)
CD45+CD3+CD56+CD107+;D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	91.36 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD107+; D29; n=1,3,1,4,4,8	19.20 (± 99999)	24.61 (± 12.809)	94.74 (± 99999)	21.97 (± 16.720)
CD45+CD3+CD56+CD107+; FU;n=1,2,0,3,1,4	19.60 (± 99999)	27.79 (± 8.132)	99999 (± 99999)	32.87 (± 23.340)
CD45+CD3+CD56+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	20.51 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD69+CD107+;D1; pre; n=1,3,1,5,4,9	8.10 (± 99999)	23.26 (± 2.974)	30.77 (± 99999)	23.85 (± 14.628)
CD45+CD3+CD56+CD69+CD107+;D1; 1 h;n=1,3,1,5,4,9	15.15 (± 99999)	25.29 (± 8.566)	16.67 (± 99999)	24.96 (± 14.211)
CD45+CD3+CD56+CD69+CD107+;D1; 6 h;n=1,3,1,5,4,11	17.14 (± 99999)	26.84 (± 8.938)	77.27 (± 99999)	24.77 (± 15.022)
CD45+CD3+CD56+CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	50.00 (± 99999)	12.24 (± 3.111)
CD45+CD3+CD56+CD69+CD107+; D8; n=1,3,0,5,4,8	32.08 (± 99999)	24.24 (± 11.427)	99999 (± 99999)	22.33 (± 5.946)
CD45+CD3+CD56+CD69+CD107+; D15;S1; n=1,3,1,5,4,9	24.12 (± 99999)	16.22 (± 9.646)	66.67 (± 99999)	19.78 (± 15.294)
CD45+CD3+CD56+CD69+CD107+;D15 ;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	85.45 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD69+CD107+; D29; n=1,3,1,4,4,8	18.67 (± 99999)	24.31 (± 12.597)	86.84 (± 99999)	21.41 (± 16.520)
CD45+CD3+CD56+CD69+CD107+; FU;n=1,2,0,3,1,4	19.60 (± 99999)	27.48 (± 8.217)	99999 (± 99999)	31.89 (± 22.622)
CD45+CD3+CD56+CD69+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	16.67 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD69+CD107-;D1; pre; n=1,3,1,5,4,9	54.70 (± 99999)	54.57 (± 2.810)	53.85 (± 99999)	52.20 (± 11.519)
CD45+CD3+CD56+CD69+CD107-;D1;1 h;n=1,3,1,5,4,9	56.06 (± 99999)	52.62 (± 3.308)	83.33 (± 99999)	49.72 (± 10.923)
CD45+CD3+CD56+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11	60.00 (± 99999)	49.71 (± 2.501)	22.73 (± 99999)	50.88 (± 11.326)
CD45+CD3+CD56+CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	40.00 (± 99999)	67.28 (± 8.719)
CD45+CD3+CD56+CD69+CD107-; D8; n=1,3,0,5,4,8	38.27 (± 99999)	55.17 (± 6.740)	99999 (± 99999)	54.92 (± 10.367)
CD45+CD3+CD56+CD69+CD107-; D15;S1; n=1,3,1,5,4,9	52.41 (± 99999)	65.04 (± 6.660)	33.33 (± 99999)	56.94 (± 9.081)

CD45+CD3+CD56+CD69+CD107-; ;D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	5.45 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD69+CD107-; D29; n=1,3,1,4,4,8	57.87 (± 99999)	60.14 (± 4.928)	5.26 (± 99999)	53.70 (± 12.139)
CD45+CD3+CD56+CD69+CD107-; FU;n=1,2,0,3,1,4	57.35 (± 99999)	56.28 (± 5.240)	99999 (± 99999)	45.05 (± 22.028)
CD45+CD3+CD56+CD69+CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	56.41 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD69- CD107+;D1pre; n=1,3,1,5,4,9	0.00 (± 99999)	0.19 (± 0.163)	0.00 (± 99999)	0.84 (± 1.119)
CD45+CD3+CD56+CD69-CD107+;D1;1 h;n=1,3,1,5,4,9	1.01 (± 99999)	0.30 (± 0.295)	0.00 (± 99999)	0.87 (± 1.493)
CD45+CD3+CD56+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11	0.00 (± 99999)	0.72 (± 0.806)	0.00 (± 99999)	0.77 (± 1.369)
CD45+CD3+CD56+CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	0.00 (± 99999)	0.16 (± 0.219)
CD45+CD3+CD56+CD69-CD107+; D8; n=1,3,0,5,4,8	2.43 (± 99999)	0.84 (± 0.716)	99999 (± 99999)	0.37 (± 0.613)
CD45+CD3+CD56+CD69-CD107+; D15;S1;n=1,3,1,5,4,9	0.32 (± 99999)	0.17 (± 0.300)	0.00 (± 99999)	0.37 (± 0.288)
CD45+CD3+CD56+CD69- CD107+;D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	5.91 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD69-CD107+; D29; n=1,3,1,4,4,8	0.53 (± 99999)	0.29 (± 0.409)	7.89 (± 99999)	0.57 (± 0.312)
CD45+CD3+CD56+CD69-CD107+; FU;n=1,2,0,3,1,4	0.00 (± 99999)	0.31 (± 0.085)	99999 (± 99999)	0.98 (± 1.235)
CD45+CD3+CD56+CD69-CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	3.85 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD69-CD107- ;D1pre; n=1,3,1,5,4,9	37.20 (± 99999)	21.98 (± 5.814)	15.38 (± 99999)	23.11 (± 12.486)
CD45+CD3+CD56+CD69-CD107-;D1;1 h;n=1,3,1,5,4,9	27.78 (± 99999)	21.78 (± 8.736)	0.00 (± 99999)	24.444 (± 11.410)
CD45+CD3+CD56+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11	22.86 (± 99999)	22.74 (± 11.250)	0.00 (± 99999)	23.59 (± 9.836)
CD45+CD3+CD56+CD69-CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	10.00 (± 99999)	20.34 (± 11.604)
CD45+CD3+CD56+CD69-CD107-; D8; n=1,3,0,5,4,8	27.21 (± 99999)	19.75 (± 7.018)	99999 (± 99999)	22.38 (± 7.709)
CD45+CD3+CD56+CD69-CD107-; D15;S1; n=1,3,1,5,4,9	23.15 (± 99999)	18.56 (± 7.134)	0.00 (± 99999)	22.91 (± 9.852)
CD45+CD3+CD56+CD69-CD107- ;D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	3.18 (± 99999)	99999 (± 99999)
CD45+CD3+CD56+CD69-CD107-; D29; n=1,3,1,4,4,8	22.93 (± 99999)	15.25 (± 9.918)	0.00 (± 99999)	24.33 (± 5.914)
CD45+CD3+CD56+CD69-CD107-; FU;n=1,2,0,3,1,4	23.05 (± 99999)	15.94 (± 2.892)	99999 (± 99999)	22.09 (± 2.249)
CD45+CD3+CD56+CD69-CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	23.08 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+CD69+;D1pre; n=1,3,1,5,4,9	57.87 (± 99999)	71.12 (± 1.083)	59.62 (± 99999)	70.19 (± 9.089)
CD45+CD3+CD8+CD69+;D1;1 h;n=1,3,1,5,4,9	54.45 (± 99999)	66.55 (± 0.781)	66.67 (± 99999)	68.39 (± 8.060)
CD45+CD3+CD8+CD69+;D1;6 h;n=1,3,1,5,4,11	70.17 (± 99999)	64.77 (± 2.867)	81.08 (± 99999)	67.66 (± 7.411)
CD45+CD3+CD8+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	71.67 (± 99999)	77.60 (± 7.898)
CD45+CD3+CD8+CD69+; D8; n=1,3,0,5,4,8	63.60 (± 99999)	65.38 (± 2.682)	99999 (± 99999)	71.51 (± 5.945)
CD45+CD3+CD8+CD69+; D15;S1; n=1,3,1,5,4,9	66.21 (± 99999)	70.12 (± 3.641)	67.74 (± 99999)	72.11 (± 5.807)
CD45+CD3+CD8+CD69+; D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	69.60 (± 99999)	99999 (± 99999)

CD45+CD3+CD8+CD69+; D29; n=1,3,1,4,4,8	68.47 (± 99999)	72.13 (± 0.599)	52.66 (± 99999)	68.07 (± 4.666)
CD45+CD3+CD8+CD69+; FU;n=1,2,0,3,1,4	67.97 (± 99999)	74.76 (± 3.903)	99999 (± 99999)	74.36 (± 3.927)
CD45+CD3+CD8+CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	45.15 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+CD107+;D1pre; n=1,3,1,5,4,9	9.25 (± 99999)	24.58 (± 6.553)	17.31 (± 99999)	24.38 (± 10.840)
CD45+CD3+CD8+CD107+;D1;1 h;n=1,3,1,5,4,9	11.02 (± 99999)	21.64 (± 7.885)	4.17 (± 99999)	24.87 (± 10.264)
CD45+CD3+CD8+CD107+;D1;6 h;n=1,3,1,5,4,11	13.88 (± 99999)	22.21 (± 5.668)	35.14 (± 99999)	21.61 (± 12.241)
CD45+CD3+CD8+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	25.00 (± 99999)	17.03 (± 4.907)
CD45+CD3+CD8+CD107+; D8; n=1,3,0,5,4,8	37.70 (± 99999)	19.18 (± 3.660)	99999 (± 99999)	24.12 (± 11.200)
CD45+CD3+CD8+CD107+; D15; S1;n=1,3,1,5,4,9	20.58 (± 99999)	11.59 (± 2.973)	93.55 (± 99999)	21.11 (± 14.964)
CD45+CD3+CD8+CD107+; D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	90.12 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+CD107+; D29; n=1,3,1,4,4,8	44.48 (± 99999)	18.53 (± 2.105)	66.27 (± 99999)	18.44 (± 12.685)
CD45+CD3+CD8+CD107+; FU;n=1,2,0,3,1,4	21.17 (± 99999)	23.00 (± 7.545)	99999 (± 99999)	34.50 (± 27.190)
CD45+CD3+CD8+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	13.91 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+CD69+CD107+;D1pre; e; n=1,3,1,5,4,9	8.95 (± 99999)	23.82 (± 6.136)	16.35 (± 99999)	23.35 (± 10.595)
CD45+CD3+CD8+CD69+CD107+;D1;1 h;n=1,3,1,5,4,9	10.13 (± 99999)	20.60 (± 7.232)	4.17 (± 99999)	23.63 (± 10.069)
CD45+CD3+CD8+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11	13.70 (± 99999)	20.92 (± 4.681)	35.14 (± 99999)	20.61 (± 11.463)
CD45+CD3+CD8+CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	25.00 (± 99999)	16.67 (± 4.391)
CD45+CD3+CD8+CD69+CD107+; D8; n=1,3,0,5,4,8	33.65 (± 99999)	17.86 (± 1.989)	99999 (± 99999)	23.15 (± 10.176)
CD45+CD3+CD8+CD69+CD107+; D15;S1; n=1,3,1,5,4,9	19.35 (± 99999)	11.35 (± 2.815)	64.52 (± 99999)	20.62 (± 14.511)
CD45+CD3+CD8+CD69+CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	66.74 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+CD69+CD107+; D29; n=1,3,1,4,4,8	36.62 (± 99999)	18.16 (± 2.172)	44.97 (± 99999)	17.79 (± 12.221)
CD45+CD3+CD8+CD69+CD107+; FU;n=1,2,0,3,1,4	20.35 (± 99999)	22.43 (± 7.177)	99999 (± 99999)	33.05 (± 25.896)
CD45+CD3+CD8+CD69+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	12.34 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+CD69+CD107- ;D1pre; n=1,3,1,5,4,9	48.92 (± 99999)	47.30 (± 5.590)	43.27 (± 99999)	46.85 (± 9.558)
CD45+CD3+CD8+CD69+CD107-;D1;1 h;n=1,3,1,5,4,9	44.32 (± 99999)	45.95 (± 6.784)	62.50 (± 99999)	44.76 (± 7.470)
CD45+CD3+CD8+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11	56.47 (± 99999)	43.85 (± 7.548)	45.95 (± 99999)	47.05 (± 7.908)
CD45+CD3+CD8+CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	46.67 (± 99999)	60.93 (± 12.282)
CD45+CD3+CD8+CD69+CD107-; D8; n=1,3,0,5,4,8	29.96 (± 99999)	47.53 (± 4.483)	99999 (± 99999)	48.36 (± 11.067)
CD45+CD3+CD8+CD69+CD107-; D15; S1;n=1,3,1,5,4,9	46.86 (± 99999)	58.77 (± 6.439)	3.23 (± 99999)	51.49 (± 9.965)
CD45+CD3+CD8+CD69+CD107-; D15; S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	2.86 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+CD69+CD107-; D29; n=1,3,1,4,4,8	31.86 (± 99999)	53.96 (± 1.639)	7.69 (± 99999)	50.28 (± 9.182)

CD45+CD3+CD8+CD69+CD107-; FU;n=1,2,0,3,1,4	47.63 (± 99999)	52.34 (± 3.274)	99999 (± 99999)	41.31 (± 23.301)
CD45+CD3+CD8+CD69+CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	32.81 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+CD69- CD107+;D1pre; n=1,3,1,5,4,9	0.30 (± 99999)	0.76 (± 0.475)	0.96 (± 99999)	1.03 (± 1.228)
CD45+CD3+CD8+CD69-CD107+;D1;1 h;n=1,3,1,5,4,9	0.89 (± 99999)	1.03 (± 0.683)	0.00 (± 99999)	1.24 (± 1.342)
CD45+CD3+CD8+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11	0.19 (± 99999)	1.30 (± 1.040)	0.00 (± 99999)	1.01 (± 1.572)
CD45+CD3+CD8+CD69-CD107+; D8; n=1,3,0,5,4,8	4.05 (± 99999)	1.32 (± 1.711)	99999 (± 99999)	0.97 (± 1.172)
CD45+CD3+CD8+CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	0.00 (± 99999)	0.37 (± 0.516)
CD45+CD3+CD8+CD69-CD107+; D15;S1;n=1,3,1,5,4,9	1.23 (± 99999)	0.24 (± 0.163)	29.03 (± 99999)	0.48 (± 0.609)
CD45+CD3+CD8+CD69-CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	23.37 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+CD69-CD107+; D29; n=1,3,1,4,4,8	7.87 (± 99999)	0.37 (± 0.078)	21.30 (± 99999)	0.65 (± 0.554)
CD45+CD3+CD8+CD69-CD107+; FU;n=1,2,0,3,1,4	0.82 (± 99999)	0.58 (± 0.361)	99999 (± 99999)	1.44 (± 1.298)
CD45+CD3+CD8+CD69-CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	1.57 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+CD69-CD107-;D1pre; n=1,3,1,5,4,9	41.83 (± 99999)	28.12 (± 1.219)	39.42 (± 99999)	28.78 (± 8.425)
CD45+CD3+CD8+CD69-CD107-;D1;1 h;n=1,3,1,5,4,9	44.65 (± 99999)	32.42 (± 1.397)	33.33 (± 99999)	30.37 (± 7.516)
CD45+CD3+CD8+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11	29.64 (± 99999)	33.94 (± 1.914)	18.92 (± 99999)	31.34 (± 7.255)
CD45+CD3+CD8+CD69-CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	28.33 (± 99999)	22.04 (± 7.382)
CD45+CD3+CD8+CD69-CD107-; D8; n=1,3,0,5,4,8	32.34 (± 99999)	33.30 (± 2.044)	99999 (± 99999)	27.52 (± 6.239)
CD45+CD3+CD8+CD69-CD107-; D15;S1; n=1,3,1,5,4,9	32.56 (± 99999)	29.64 (± 3.488)	3.23 (± 99999)	27.41 (± 6.016)
CD45+CD3+CD8+CD69-CD107-; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	7.03 (± 99999)	99999 (± 99999)
CD45+CD3+CD8+CD69-CD107-; D29; n=1,3,1,4,4,8	23.66 (± 99999)	27.50 (± 0.558)	26.04 (± 99999)	31.28 (± 4.954)
CD45+CD3+CD8+CD69-CD107-; FU;n=1,2,0,3,1,4	31.20 (± 99999)	24.67 (± 4.264)	99999 (± 99999)	24.19 (± 5.014)
CD45+CD3+CD8+CD69-CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	53.28 (± 99999)	99999 (± 99999)
CD45+CD3+CD69+;D1pre; n=1,3,1,5,4,9	49.72 (± 99999)	64.40 (± 2.410)	61.84 (± 99999)	64.96 (± 9.980)
CD45+CD3+CD69+;D1;1 h;n=1,3,1,5,4,9	50.16 (± 99999)	60.66 (± 4.707)	67.16 (± 99999)	63.58 (± 8.122)
CD45+CD3+CD69+;D1;6 h;n=1,3,1,5,4,11	63.54 (± 99999)	61.49 (± 3.426)	80.00 (± 99999)	62.24 (± 7.910)
CD45+CD3+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	68.61 (± 99999)	69.01 (± 3.783)
CD45+CD3+CD69+; D8; n=1,3,0,5,4,8	58.04 (± 99999)	59.29 (± 5.515)	99999 (± 99999)	64.97 (± 2.165)
CD45+CD3+CD69+; D15;S1; n=1,3,1,5,4,9	53.90 (± 99999)	64.92 (± 4.016)	72.73 (± 99999)	65.08 (± 6.604)
CD45+CD3+CD69+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	67.36 (± 99999)	99999 (± 99999)
CD45+CD3+CD69+; D29; n=1,3,1,4,4,8	60.54 (± 99999)	67.97 (± 4.090)	52.79 (± 99999)	61.52 (± 6.451)
CD45+CD3+CD69+; FU;n=1,2,0,3,1,4	54.72 (± 99999)	68.87 (± 8.259)	99999 (± 99999)	68.45 (± 0.841)

CD45+CD3+CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	42.30 (± 99999)	99999 (± 99999)
CD45+CD3+CD107+;D1pre; n=1,3,1,5,4,9	3.28 (± 99999)	13.70 (± 6.236)	11.66 (± 99999)	13.13 (± 10.732)
CD45+CD3+CD107+;D1;1 h;n=1,3,1,5,4,9	3.17 (± 99999)	12.63 (± 8.846)	1.49 (± 99999)	12.84 (± 10.971)
CD45+CD3+CD107+;D1;6 h;n=1,3,1,5,4,11	5.74 (± 99999)	11.98 (± 6.511)	24.50 (± 99999)	12.53 (± 10.804)
CD45+CD3+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	15.33 (± 99999)	6.17 (± 2.397)
CD45+CD3+CD107+; D8; n=1,3,0,5,4,8	19.48 (± 99999)	9.93 (± 4.733)	99999 (± 99999)	12.31 (± 7.851)
CD45+CD3+CD107+; D15;S1; n=1,3,1,5,4,9	10.68 (± 99999)	4.32 (± 2.680)	76.14 (± 99999)	9.84 (± 7.608)
CD45+CD3+CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	84.64 (± 99999)	99999 (± 99999)
CD45+CD3+CD107+; D29; n=1,3,1,4,4,8	11.62 (± 99999)	9.24 (± 3.455)	54.47 (± 99999)	11.88 (± 12.246)
CD45+CD3+CD107+; FU;n=1,2,0,3,1,4	6.07 (± 99999)	11.19 (± 6.124)	99999 (± 99999)	27.28 (± 11.058)
CD45+CD3+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	11.62 (± 99999)	99999 (± 99999)
CD45+CD3+CD69+CD107+;D1pre; n=1,3,1,5,4,9	3.22 (± 99999)	13.33 (± 5.965)	11.31 (± 99999)	12.68 (± 10.738)
CD45+CD3+CD69+CD107+;D1;1 h;n=1,3,1,5,4,9	3.04 (± 99999)	12.15 (± 8.408)	1.49 (± 99999)	12.33 (± 10.922)
CD45+CD3+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11	5.63 (± 99999)	11.29 (± 5.756)	24.50 (± 99999)	12.00 (± 10.573)
CD45+CD3+CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	15.33 (± 99999)	6.02 (± 2.220)
CD45+CD3+CD69+CD107+; D8; n=1,3,0,5,4,8	17.91 (± 99999)	9.29 (± 3.881)	99999 (± 99999)	11.95 (± 7.603)
CD45+CD3+CD69+CD107+; D15;S1 ; n=1,3,1,5,4,9	9.81 (± 99999)	4.25 (± 2.622)	62.5 (± 99999)	9.63 (± 7.568)
CD45+CD3+CD69+CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	61.21 (± 99999)	99999 (± 99999)
CD45+CD3+CD69+CD107+; D29; n=1,3,1,4,4,8	10.28 (± 99999)	9.07 (± 3.421)	40.50 (± 99999)	11.47 (± 11.821)
CD45+CD3+CD69+CD107+; FU;n=1,2,0,3,1,4	5.92 (± 99999)	10.98 (± 5.961)	99999 (± 99999)	26.15 (± 10.446)
CD45+CD3+CD69+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	10.47 (± 99999)	99999 (± 99999)
CD45+CD3+CD69+CD107-;D1pre; n=1,3,1,5,4,9	46.49 (± 99999)	51.06 (± 3.578)	50.53 (± 99999)	52.28 (± 8.029)
CD45+CD3+CD69+CD107-;D1;1 h;n=1,3,1,5,4,9	47.13 (± 99999)	48.51 (± 4.092)	65.67 (± 99999)	51.25 (± 7.800)
CD45+CD3+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11	57.91 (± 99999)	50.20 (± 6.989)	55.50 (± 99999)	50.24 (± 5.794)
CD45+CD3+CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	53.28 (± 99999)	62.99 (± 6.003)
CD45+CD3+CD69+CD107-; D8; n=1,3,0,5,4,8	40.13 (± 99999)	50.00 (± 5.550)	99999 (± 99999)	53.02 (± 7.641)
CD45+CD3+CD69+CD107-; D15; S1; n=1,3,1,5,4,9	44.09 (± 99999)	60.67 (± 5.732)	10.23 (± 99999)	55.45 (± 4.502)
CD45+CD3+CD69+CD107-; D15; S2;n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)	6.15 (± 99999)	99999 (± 99999)
CD45+CD3+CD69+CD107-; D29; n=1,3,1,4,4,8	50.26 (± 99999)	58.89 (± 0.756)	12.29 (± 99999)	50.05 (± 6.415)
CD45+CD3+CD69+CD107-; FU;n=1,2,0,3,1,4	48.79 (± 99999)	57.90 (± 2.298)	99999 (± 99999)	42.29 (± 9.606)
CD45+CD3+CD69+CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	31.83 (± 99999)	99999 (± 99999)

CD45+CD3+CD69-CD107+;D1pre; n=1,3,1,5,4,9	0.06 (± 99999)	0.36 (± 0.277)	0.35 (± 99999)	0.45 (± 0.579)
CD45+CD3+CD69-CD107+;D1;1 h;n=1,3,1,5,4,9	0.13 (± 99999)	0.47 (± 0.451)	0.00 (± 99999)	0.50 (± 0.615)
CD45+CD3+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11	0.11 (± 99999)	0.69 (± 0.777)	0.00 (± 99999)	0.54 (± 0.844)
CD45+CD3+CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	0.00 (± 99999)	0.15 (± 0.177)
CD45+CD3+CD69-CD107+; D8; n=1,3,0,5,4,8	1.57 (± 99999)	0.64 (± 0.861)	99999 (± 99999)	0.35 (± 3.392)
CD45+CD3+CD69-CD107+; D15; S1; n=1,3,1,5,4,9	0.86 (± 99999)	0.07 (± 0.059)	13.64 (± 99999)	0.21 (± 0.187)
CD45+CD3+CD69-CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	23.43 (± 99999)	99999 (± 99999)
CD45+CD3+CD69-CD107+; D29; n=1,3,1,4,4,8	1.34 (± 99999)	0.17 (± 0.042)	13.97 (± 99999)	0.41 (± 0.476)
CD45+CD3+CD69-CD107+; FU;n=1,2,0,3,1,4	0.15 (± 99999)	0.23 (± 0.163)	99999 (± 99999)	1.13 (± 0.705)
CD45+CD3+CD69-CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	1.16 (± 99999)	99999 (± 99999)
CD45+CD3+CD69-CD107-;D1pre; n=1,3,1,5,4,9	50.23 (± 99999)	35.23 (± 2.664)	37.81 (± 99999)	34.58 (± 9.638)
CD45+CD3+CD69-CD107-;D1;1 h;n=1,3,1,5,4,9	49.71 (± 99999)	38.87 (± 5.156)	32.84 (± 99999)	35.91 (± 7.854)
CD45+CD3+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11	36.35 (± 99999)	37.83 (± 3.625)	20.00 (± 99999)	37.23 (± 7.810)
CD45+CD3+CD69-CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	31.39 (± 99999)	30.85 (± 3.606)
CD45+CD3+CD69-CD107-; D8; n=1,3,0,5,4,8	40.39 (± 99999)	40.07 (± 5.758)	99999 (± 99999)	34.67 (± 2.320)
CD45+CD3+CD69-CD107-; D15;S1; n=1,3,1,5,4,9	45.24 (± 99999)	35.01 (± 3.981)	13.64 (± 99999)	34.71 (± 6.524)
CD45+CD3+CD69-CD107-; D15; S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	9.2 (± 99999)	99999 (± 99999)
CD45+CD3+CD69-CD107-; D29; n=1,3,1,4,4,8	38.12 (± 99999)	31.87 (± 4.127)	33.24 (± 99999)	38.07 (± 6.801)
CD45+CD3+CD69-CD107-; FU;n=1,2,0,3,1,4	45.14 (± 99999)	30.91 (± 8.422)	99999 (± 99999)	30.43 (± 1.483)
CD45+CD3+CD69-CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	56.55 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-CD69+;D1pre; n=1,3,1,5,4,9	47.90 (± 99999)	61.18 (± 3.198)	63.79 (± 99999)	60.39 (± 9.372)
CD45+CD3+CD8-CD69+;D1;1 h;n=1,3,1,5,4,9	49.15 (± 99999)	58.34 (± 5.829)	67.19 (± 99999)	60.93 (± 7.196)
CD45+CD3+CD8-CD69+;D1;6 h;n=1,3,1,5,4,11	62.61 (± 99999)	60.24 (± 3.832)	77.59 (± 99999)	58.97 (± 6.452)
CD45+CD3+CD8-CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	67.11 (± 99999)	63.36 (± 5.169)
CD45+CD3+CD8-CD69+; D8; n=1,3,0,5,4,8	57.28 (± 99999)	56.36 (± 7.227)	99999 (± 99999)	61.41 (± 3.385)
CD45+CD3+CD8-CD69+; D15; S1;n=1,3,1,5,4,9	47.62 (± 99999)	64.16 (± 6.272)	75.86 (± 99999)	61.57 (± 4.769)
CD45+CD3+CD8-CD69+; D15; S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	66.87 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-CD69+; D29; n=1,3,1,4,4,8	59.17 (± 99999)	66.23 (± 5.538)	54.82 (± 99999)	57.72 (± 3.694)
CD45+CD3+CD8-CD69+; FU;n=1,2,0,3,1,4	52.89 (± 99999)	65.54 (± 8.811)	99999 (± 99999)	62.68 (± 3.581)
CD45+CD3+CD8-CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	41.04 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-CD107+;D1pre; n=1,3,1,5,4,9	1.89 (± 99999)	8.52 (± 6.264)	8.62 (± 99999)	9.13 (± 7.030)

CD45+CD3+CD8-CD107+;D1;1 h;n=1,3,1,5,4,9	2.05 (± 99999)	9.13 (± 9.350)	0.00 (± 99999)	8.77 (± 6.304)
CD45+CD3+CD8-CD107+;D1;6 h;n=1,3,1,5,4,11	4.79 (± 99999)	8.43 (± 6.165)	14.66 (± 99999)	10.25 (± 7.708)
CD45+CD3+CD8-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	7.89 (± 99999)	22.06 (± 12.183)
CD45+CD3+CD8-CD107+; D8; n=1,3,0,5,4,8	16.59 (± 99999)	5.43 (± 4.942)	99999 (± 99999)	8.44 (± 5.762)
CD45+CD3+CD8-CD107+; D15; S1;n=1,3,1,5,4,9	8.04 (± 99999)	4.31 (± 2.868)	67.24 (± 99999)	7.32 (± 4.700)
CD45+CD3+CD8-CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	79.79 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-CD107+; D29; n=1,3,1,4,4,8	6.04 (± 99999)	5.33 (± 3.967)	45.69 (± 99999)	7.99 (± 2.600)
CD45+CD3+CD8-CD107+; FU;n=1,2,0,3,1,4	3.99 (± 99999)	12.22 (± 14.015)	99999 (± 99999)	16.79 (± 8.978)
CD45+CD3+CD8-CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	10.62 (± 99999)	99999 (± 99999)
CD45+CD3+CD8- CD69+CD107+;D1pre; n=1,3,1,5,4,9	1.88 (± 99999)	8.34 (± 6.086)	8.62 (± 99999)	8.66 (± 6.705)
CD45+CD3+CD8-CD69+CD107+;D1;1 h;n=1,3,1,5,4,9	2.03 (± 99999)	8.84 (± 8.957)	0.00 (± 99999)	8.39 (± 6.132)
CD45+CD3+CD8-CD69+CD107+;D1;6 h;n=1,3,1,5,4,11	4.69 (± 99999)	7.99 (± 5.509)	14.66 (± 99999)	9.81 (± 7.518)
CD45+CD3+CD8-CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	7.89 (± 99999)	20.45 (± 10.684)
CD45+CD3+CD8-CD69+CD107+; D8; n=1,3,0,5,4,8	15.40 (± 99999)	5.16 (± 4.542)	99999 (± 99999)	8.22 (± 5.569)
CD45+CD3+CD8-CD69+CD107+; D15; S1;n=1,3,1,5,4,9	7.37 (± 99999)	4.28 (± 2.851)	62.07 (± 99999)	7.09 (± 4.543)
CD45+CD3+CD8-CD69+CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	58.06 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-CD69+CD107+; D29; n=1,3,1,4,4,8	5.81 (± 99999)	5.26 (± 3.913)	38.58 (± 99999)	7.39 (± 1.938)
CD45+CD3+CD8-CD69+CD107+; FU;n=1,2,0,3,1,4	3.94 (± 99999)	11.93 (± 13.598)	99999 (± 99999)	16.09 (± 8.306)
CD45+CD3+CD8-CD69+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	9.71 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-CD69+CD107-;D1pre; n=1,3,1,5,4,9	46.02 (± 99999)	52.84 (± 2.952)	55.17 (± 99999)	51.72 (± 7.637)
CD45+CD3+CD8-CD69+CD107-;D1;1 h;n=1,3,1,5,4,9	47.12 (± 99999)	49.48 (± 3.288)	67.19 (± 99999)	52.53 (± 6.408)
CD45+CD3+CD8-CD69+CD107-;D1;6 h;n=1,3,1,5,4,11	57.92 (± 99999)	52.25 (± 6.443)	62.93 (± 99999)	49.16 (± 4.649)
CD45+CD3+CD8-CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	59.21 (± 99999)	42.91 (± 5.515)
CD45+CD3+CD8-CD69+CD107-; D8; n=1,3,0,5,4,8	41.88 (± 99999)	51.21 (± 6.451)	99999 (± 99999)	53.19 (± 5.196)
CD45+CD3+CD8-CD69+CD107-; D15;S1; n=1,3,1,5,4,9	40.25 (± 99999)	59.88 (± 3.546)	13.79 (± 99999)	54.48 (± 6.572)
CD45+CD3+CD8-CD69+CD107-; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	8.81 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-CD69+CD107-; D29; n=1,3,1,4,4,8	53.36 (± 99999)	60.98 (± 1.681)	16.24 (± 99999)	50.33 (± 5.623)
CD45+CD3+CD8-CD69+CD107-; FU;n=1,2,0,3,1,4	48.95 (± 99999)	53.62 (± 4.794)	99999 (± 99999)	46.59 (± 4.968)
CD45+CD3+CD8-CD69+CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	31.33 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-CD69-CD107+;D1pre; n=1,3,1,5,4,9	0.01 (± 99999)	0.17 (± 0.180)	0.00 (± 99999)	0.47 (± 0.607)
CD45+CD3+CD8-CD69-CD107+;D1;1 h;n=1,3,1,5,4,9	0.03 (± 99999)	0.27 (± 0.414)	0.00 (± 99999)	0.38 (± 0.526)

CD45+CD3+CD8-CD69-CD107+;D1;6 h;n=1,3,1,5,4,11	0.11 (± 99999)	0.44 (± 0.691)	0.00 (± 99999)	0.44 (± 0.695)
CD45+CD3+CD8-CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	0.00 (± 99999)	1.62 (± 1.492)
CD45+CD3+CD8-CD69-CD107+; D8; n=1,3,0,5,4,8	1.19 (± 99999)	0.27 (± 0.406)	99999 (± 99999)	0.22 (± 0.239)
CD45+CD3+CD8-CD69-CD107+; D15;S1; n=1,3,1,5,4,9	0.66 (± 99999)	0.02 (± 0.020)	5.17 (± 99999)	0.23 (± 0.217)
CD45+CD3+CD8-CD69-CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	21.74 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-CD69-CD107+; D29; n=1,3,1,4,4,8	0.24 (± 99999)	0.08 (± 0.057)	7.11 (± 99999)	0.60 (± 0.787)
CD45+CD3+CD8-CD69-CD107+; FU;n=1,2,0,3,1,4	0.05 (± 99999)	0.30 (± 0.417)	99999 (± 99999)	0.70 (± 0.729)
CD45+CD3+CD8-CD69-CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	0.91 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-CD69-CD107-;D1pre; n=1,3,1,5,4,9	52.08 (± 99999)	38.64 (± 3.370)	36.21 (± 99999)	39.14 (± 9.186)
CD45+CD3+CD8-CD69-CD107-;D1;1 h;n=1,3,1,5,4,9	50.83 (± 99999)	41.39 (± 6.239)	32.81 (± 99999)	38.69 (± 6.983)
CD45+CD3+CD8-CD69-CD107-;D1;6 h;n=1,3,1,5,4,11	37.28 (± 99999)	39.32 (± 4.165)	22.41 (± 99999)	40.59 (± 6.401)
CD45+CD3+CD8-CD69-CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	32.89 (± 99999)	35.03 (± 6.661)
CD45+CD3+CD8-CD69-CD107-; D8; n=1,3,0,5,4,8	41.53 (± 99999)	43.36 (± 7.367)	99999 (± 99999)	38.37 (± 3.532)
CD45+CD3+CD8-CD69-CD107-; D15;S1;n=1,3,1,5,4,9	51.72 (± 99999)	35.82 (± 6.285)	18.97 (± 99999)	38.20 (± 4.657)
CD45+CD3+CD8-CD69-CD107-; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	11.4 (± 99999)	99999 (± 99999)
CD45+CD3+CD8-CD69-CD107-; D29; n=1,3,1,4,4,8	40.59 (± 99999)	33.69 (± 5.590)	38.07 (± 99999)	41.69 (± 3.048)
CD45+CD3+CD8-CD69-CD107-; FU;n=1,2,0,3,1,4	47.06 (± 99999)	34.17 (± 9.228)	99999 (± 99999)	36.61 (± 4.300)
CD45+CD3+CD8-CD69-CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	58.05 (± 99999)	99999 (± 99999)
CD45+CD3-CD19+CD69+;D1pre; n=1,3,1,5,4,9	75.76 (± 99999)	67.04 (± 8.518)	84.75 (± 99999)	70.41 (± 7.715)
CD45+CD3-CD19+CD69+;D1;1 h;n=1,3,1,5,4,9	80.05 (± 99999)	66.03 (± 12.856)	100.00 (± 99999)	72.80 (± 9.542)
CD45+CD3-CD19+CD69+;D1;6 h;n=1,3,1,5,4,11	78.69 (± 99999)	69.97 (± 8.412)	84.21 (± 99999)	68.55 (± 5.810)
CD45+CD3-CD19+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	100.00 (± 99999)	71.53 (± 0.721)
CD45+CD3-CD19+CD69+; D8; n=1,3,0,5,4,8	72.44 (± 99999)	62.85 (± 5.952)	99999 (± 99999)	70.60 (± 5.653)
CD45+CD3-CD19+CD69+; D15;S1; n=1,3,1,5,4,9	71.85 (± 99999)	64.28 (± 7.449)	89.47 (± 99999)	70.07 (± 6.942)
CD45+CD3-CD19+CD69+; D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	85.95 (± 99999)	99999 (± 99999)
CD45+CD3-CD19+CD69+; D29; n=1,3,1,4,4,8	74.65 (± 99999)	72.22 (± 17.828)	66.18 (± 99999)	68.83 (± 5.767)
CD45+CD3-CD19+CD69+; FU;n=1,2,0,3,1,4	74.67 (± 99999)	68.44 (± 5.268)	99999 (± 99999)	73.60 (± 7.363)
CD45+CD3-CD19+CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	60.00 (± 99999)	99999 (± 99999)
CD45+CD14+CD69+;D1pre; n=1,3,1,5,4,9	99.66 (± 99999)	99.57 (± 0.371)	100.00 (± 99999)	99.27 (± 0.308)
CD45+CD14+CD69+;D1;1 h;n=1,3,1,5,4,9	99.86 (± 99999)	99.54 (± 0.204)	99.55 (± 99999)	99.42 (± 0.202)
CD45+CD14+CD69+;D1;6 h;n=1,3,1,5,4,11	99.45 (± 99999)	99.19 (± 0.239)	99.78 (± 99999)	99.28 (± 0.393)

CD45+CD14+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99999 (± 99999)	100.00 (± 99999)	99.16 (± 1.018)
CD45+CD14+CD69+; D8; n=1,3,0,5,4,8	99.41 (± 99999)	99.49 (± 0.297)	99999 (± 99999)	99.15 (± 0.763)
CD45+CD14+CD69+; D15; S1; n=1,3,1,5,4,9	99.37 (± 99999)	99.70 (± 0.145)	100.00 (± 99999)	99.71 (± 0.311)
CD45+CD14+CD69+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	99.74 (± 99999)	99999 (± 99999)
CD45+CD14+CD69+; D29; n=1,3,1,4,4,8	99.66 (± 99999)	99.61 (± 0.391)	98.85 (± 99999)	99.53 (± 0.379)
CD45+CD14+CD69+; FU;n=1,2,0,3,1,4	99.71 (± 99999)	99.66 (± 0.028)	99999 (± 99999)	99.62 (± 0.219)
CD45+CD14+CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)	96.17 (± 99999)	99999 (± 99999)

Notes:

[106] - PD Population

[107] - PD Population

[108] - PD Population

[109] - PD Population

End point values	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4 ^[110]	12 ^[111]		
Units: Percentage of CD marker cells				
arithmetic mean (standard deviation)				
CD45+; D1; pre; n=1, 3, 1, 5, 4, 9	99.93 (± 0.050)	101.57 (± 6.268)		
CD45+; D1; 1 h; n=1, 3, 1, 5, 4, 9	99.93 (± 0.050)	101.13 (± 4.656)		
CD45+; D1; 6 h; n=1, 3, 1, 5, 4, 11	99.93 (± 0.096)	101.02 (± 3.978)		
CD45+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	99.80 (± 99999)		
CD45+; D8; n=1, 3, 0, 5, 4, 8	99.80 (± 0.400)	99.75 (± 0.576)		
CD45+; D15;S1; n=1, 3, 1, 5, 4, 9	99.78 (± 0.320)	100.33 (± 2.495)		
CD45+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+; D29; n=1, 3, 1, 4, 4, 8	99.75 (± 0.436)	100.80 (± 3.746)		
CD45+; follow-up (FU); n=1, 2, 0, 3, 1, 4	99.30 (± 99999)	101.60 (± 4.827)		
CD45+; unscheduled (USC); n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+; D1; pre;n=1, 3, 1, 5, 4, 9	71.98 (± 10.832)	72.91 (± 8.027)		
CD45+CD3+; D1; 1 h; n=1, 3, 1, 5, 4, 9	75.80 (± 6.933)	74.36 (± 9.552)		
CD45+CD3+; D1; 6 h; n=1, 3, 1, 5, 4, 11	77.83 (± 5.065)	72.16 (± 10.282)		
CD45+CD3+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	77.00 (± 99999)		
CD45+CD3+; D8; n=1, 3, 0, 5, 4, 8	77.53 (± 7.566)	75.31 (± 8.234)		
CD45+CD3+; D15; S1; n=1, 3, 1, 5, 4, 9	76.08 (± 8.844)	76.50 (± 5.723)		

CD45+CD3+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+; D29; n=1, 3, 1, 4, 4, 8	73.58 (± 9.783)	74.49 (± 12.798)		
CD45+CD3+; FU; n=1, 2, 0, 3, 1, 4	42.50 (± 99999)	70.13 (± 11.425)		
CD45+CD3+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+; D1; pre;n=1, 3, 1, 5, 4, 9	24.95 (± 13.644)	25.39 (± 11.076)		
CD45+CD3+CD8+; D1; 1 h; n=1, 3, 1, 5, 4, 9	20.48 (± 10.935)	23.18 (± 10.434)		
CD45+CD3+CD8+; D1; 6 h; n=1, 3, 1, 5, 4, 11	23.38 (± 11.738)	22.86 (± 11.701)		
CD45+CD3+CD8+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	40.60 (± 99999)		
CD45+CD3+CD8+; D8; n=1, 3, 0, 5, 4, 8	24.60 (± 12.511)	23.76 (± 9.382)		
CD45+CD3+CD8+; D15; S1; n=1, 3, 1, 5, 4, 9	26.25 (± 13.843)	27.00 (± 11.668)		
CD45+CD3+CD8+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+; D29; n=1, 3, 1, 4, 4, 8	23.05 (± 11.997)	20.40 (± 13.234)		
CD45+CD3+CD8+; FU; n=1, 2, 0, 3, 1, 4	6.30 (± 99999)	31.88 (± 4.661)		
CD45+CD3+CD8+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-; D1; pre n=1, 3, 1, 5, 4, 9	45.58 (± 4.365)	47.71 (± 14.059)		
CD45+CD3+CD8-; D1; 1 h; n=1, 3, 1, 5, 4, 9	53.90 (± 6.349)	51.10 (± 17.633)		
CD45+CD3+CD8-; D1; 6 h; n=1, 3, 1, 5, 4, 11	53.28 (± 10.943)	49.26 (± 17.654)		
CD45+CD3+CD8-; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	36.60 (± 99999)		
CD45+CD3+CD8-; D8; n=1, 3, 0, 5, 4, 8	51.70 (± 11.040)	51.48 (± 8.065)		
CD45+CD3+CD8-; D15; S1; n=1, 3, 1, 5, 4, 9	49.60 (± 9.910)	49.08 (± 13.029)		
CD45+CD3+CD8-; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-; D29; n=1, 3, 1, 4, 4, 8	50.43 (± 3.402)	54.63 (± 13.806)		
CD45+CD3+CD8-; FU; n=1, 2, 0, 3, 1, 4	36.90 (± 99999)	37.53 (± 16.020)		
CD45+CD3+CD8-; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+; D1; pre n=1, 3, 1, 5, 4, 9	13.83 (± 12.467)	10.63 (± 8.253)		
CD45+CD3-CD16+; D1; 1 h; n=1, 3, 1, 5, 4, 9	8.00 (± 8.198)	8.90 (± 6.203)		
CD45+CD3-CD16+; D1; 6 h; n=1, 3, 1, 5, 4, 11	6.43 (± 4.407)	7.44 (± 4.569)		
CD45+CD3-CD16+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	4.10 (± 99999)		
CD45+CD3-CD16+; D8; n=1, 3, 0, 5, 4, 8	9.23 (± 5.762)	11.23 (± 7.852)		
CD45+CD3-CD16+; D15; S1; n=1, 3, 1, 5, 4, 9	9.50 (± 6.470)	10.33 (± 7.555)		
CD45+CD3-CD16+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		

CD45+CD3-CD16+; D29; n=1, 3, 1, 4, 4, 8	10.73 (± 9.999)	11.93 (± 7.323)		
CD45+CD3-CD16+; FU; n=1, 2, 0, 3, 1, 4	43.50 (± 99999)	10.03 (± 10.920)		
CD45+CD3-CD16+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+; D1; pre; n=1, 3, 1, 5, 4, 9	15.93 (± 11.588)	12.16 (± 7.479)		
CD45+CD3-CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9	10.50 (± 7.470)	10.74 (± 6.300)		
CD45+CD3-CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11	9.43 (± 3.079)	10.71 (± 7.319)		
CD45+CD3-CD56+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	5.60 (± 99999)		
CD45+CD3-CD56+; D8; n=1, 3, 0, 5, 4, 8	11.10 (± 4.808)	12.33 (± 7.733)		
CD45+CD3-CD56+; D15; S1; n=1, 3, 1, 5, 4, 9	11.73 (± 6.548)	8.39 (± 4.622)		
CD45+CD3-CD56+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+; D29; n=1, 3, 1, 4, 4, 8	13.73 (± 9.582)	12.48 (± 9.517)		
CD45+CD3-CD56+; FU; n=1, 2, 0, 3, 1, 4	44.20 (± 99999)	11.95 (± 8.912)		
CD45+CD3-CD56+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+; D1; pre; n=1, 3, 1, 5, 4, 9	6.20 (± 4.774)	4.67 (± 2.707)		
CD45+CD3+CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9	6.65 (± 7.102)	4.20 (± 3.321)		
CD45+CD3+CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11	8.50 (± 10.745)	4.17 (± 3.299)		
CD45+CD3+CD56+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	7.00 (± 99999)		
CD45+CD3+CD56+; D8; n=1, 3, 0, 5, 4, 8	5.83 (± 2.756)	3.49 (± 2.801)		
CD45+CD3+CD56+; D15; S1; n=1, 3, 1, 5, 4, 9	8.15 (± 3.746)	4.43 (± 3.015)		
CD45+CD3+CD56+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+; D29; n=1, 3, 1, 4, 4, 8	11.78 (± 9.751)	2.91 (± 2.635)		
CD45+CD3+CD56+; FU; n=1, 2, 0, 3, 1, 4	3.50 (± 99999)	5.10 (± 2.665)		
CD45+CD3+CD56+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD56+; D1; pre; n=1, 3, 1, 5, 4, 9	13.25 (± 12.307)	9.58 (± 7.480)		
CD45+CD3-CD16+CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9	7.65 (± 8.118)	7.98 (± 5.768)		
CD45+CD3-CD16+CD56+; D1; 6 h; n=1,3,1,5,4,11	6.10 (± 4.221)	6.22 (± 4.445)		
CD45+CD3-CD16+CD56+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	4.10 (± 99999)		
CD45+CD3-CD16+CD56+; D8; n=1, 3, 0, 5, 4, 8	8.68 (± 5.465)	8.96 (± 6.217)		
CD45+CD3-CD16+CD56+; D15; S1; n=1, 3, 1, 5, 4, 9	8.88 (± 6.357)	6.54 (± 4.360)		
CD45+CD3-CD16+CD56+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD56+; D29; n=1, 3, 1, 4, 4, 8	10.18 (± 9.932)	9.30 (± 6.776)		

CD45+CD3-CD16+CD56+; FU; n=1, 2, 0, 3, 1, 4	41.90 (± 99999)	9.20 (± 9.937)		
CD45+CD3-CD16+CD56+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD19+; D1; pre n=1, 3, 1, 5, 4, 9	9.48 (± 4.769)	8.39 (± 3.194)		
CD45+CD3-CD19+; D1;1 h; n=1, 3, 1, 5, 4, 9	11.53 (± 6.211)	9.18 (± 3.819)		
CD45+CD3-CD19+; D1;6 h; n=1,3,1,5,4,11	10.83 (± 6.636)	9.00 (± 4.988)		
CD45+CD3-CD19+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	10.90 (± 99999)		
CD45+CD3-CD19+; D8; n=1, 3, 0, 5, 4, 8	9.63 (± 4.786)	7.65 (± 4.176)		
CD45+CD3-CD19+; D15; S1; n=1, 3, 1, 5, 4, 9	9.25 (± 4.339)	8.90 (± 4.170)		
CD45+CD3-CD19+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD19+; D29; n=1, 3, 1, 4, 4, 8	10.53 (± 6.106)	7.44 (± 4.324)		
CD45+CD3-CD19+; FU; n=1, 2, 0, 3, 1, 4	8.90 (± 99999)	8.33 (± 6.019)		
CD45+CD3-CD19+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD14+; D1; pre; n=1, 3, 1, 5, 4, 9	7.15 (± 2.029)	4.87 (± 1.406)		
CD45+CD14+; D1;1 h; n=1, 3, 1, 5, 4, 9	4.68 (± 2.926)	3.52 (± 1.713)		
CD45+CD14+; D1;6 h; n=1,3,1,5,4,11	5.80 (± 2.389)	5.23 (± 2.581)		
CD45+CD14+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	4.40 (± 99999)		
CD45+CD14+; D8; n=1, 3, 0, 5, 4, 8	7.10 (± 2.223)	5.40 (± 2.115)		
CD45+CD14+; D15; S1; n=1, 3, 1, 5, 4, 9	6.93 (± 1.823)	5.47 (± 3.061)		
CD45+CD14+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD14+; D29; n=1, 3, 1, 4, 4, 8	6.68 (± 2.241)	4.61 (± 1.108)		
CD45+CD14+; FU; n=1, 2, 0, 3, 1, 4	2.70 (± 99999)	4.98 (± 1.692)		
CD45+CD14+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD69+; D1; pre; n=1, 3, 1, 5, 4, 9	82.50 (± 3.378)	75.71 (± 15.845)		
CD45+CD3-CD16+CD69+; D1;1 h; n=1, 3, 1, 5, 4, 9	86.01 (± 3.898)	78.53 (± 16.993)		
CD45+CD3-CD16+CD69+; D1;6 h; n=1,3,1,5,4,11	84.57 (± 4.448)	79.79 (± 12.178)		
CD45+CD3-CD16+CD69+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	88.05 (± 99999)		
CD45+CD3-CD16+CD69+; D8; n=1, 3, 0, 5, 4, 8	79.91 (± 2.014)	70.93 (± 21.532)		
CD45+CD3-CD16+CD69+; D15;S1; n=1, 3, 1, 5, 4, 9	81.68 (± 7.216)	78.53 (± 20.178)		
CD45+CD3-CD16+CD69+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD69+; D29; n=1, 3, 1, 4, 4, 8	83.00 (± 6.240)	74.56 (± 17.788)		
CD45+CD3-CD16+CD69+; FU; n=1, 2, 0, 3, 1, 4	76.46 (± 99999)	80.85 (± 19.555)		
CD45+CD3-CD16+CD69+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		

CD45+CD3-CD16+CD107+; D1; pre; n=1, 3, 1, 5, 4, 9	23.96 (± 12.309)	25.04 (± 30.481)		
CD45+CD3-CD16+CD107+; D1;1 h; n=1, 3, 1, 5,4,9	24.66 (± 13.827)	23.16 (± 24.866)		
CD45+CD3-CD16+CD107+; D1;6 h; n=1,3,1,5,4,11	21.55 (± 12.001)	21.82 (± 17.204)		
CD45+CD3-CD16+CD107+; D2; n=0, 0, 1, 2, 0, 1	99999 (± 99999)	30.82 (± 99999)		
CD45+CD3-CD16+CD107+; D8; n=1, 3, 0, 5, 4, 8	14.43 (± 1.615)	27.85 (± 27.884)		
CD45+CD3-CD16+CD107+; D15; S1; n=1, 3, 1, 5, 4, 9	18.30 (± 3.558)	21.68 (± 15.816)		
CD45+CD3-CD16+CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD107+; D29; n=1, 3, 1, 4, 4, 8	27.70 (± 12.686)	17.22 (± 6.799)		
CD45+CD3-CD16+CD107+; FU; n=1, 2, 0, 3, 1, 4	11.64 (± 99999)	27.42 (± 15.633)		
CD45+CD3-CD16+CD107+; USC; n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD69+CD107+; D1; pre; n=1,3,1,5,4,9	23.53 (± 11.967)	24.68 (± 30.659)		
CD45+CD3-CD16+CD69+CD107+; D1;1 h;n=1,3,1,5,4,9	24.42 (± 13.709)	22.85 (± 24.965)		
CD45+CD3-CD16+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11	21.33 (± 11.655)	21.34 (± 17.411)		
CD45+CD3-CD16+CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	30.19 (± 99999)		
CD45+CD3-CD16+CD69+CD107+; D8; n=1,3,0,5,4,8	14.40 (± 1.591)	27.19 (± 27.949)		
CD45+CD3-CD16+CD69+CD107+; D15; S1;n=1,3,1,5,4,9	18.11 (± 3.584)	21.11 (± 16.206)		
CD45+CD3-CD16+CD69+CD107+; D15; S2;n=0,0,1,0,0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD69+CD107+; D29; n=1,3,1,4,4,8	27.36 (± 12.492)	16.08 (± 6.127)		
CD45+CD3-CD16+CD69+CD107+; FU; n=1,2,0,3,1,4	11.56 (± 99999)	27.16 (± 15.866)		
CD45+CD3-CD16+CD69+CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD69+CD107-; D1;pre; n=1,3,1,5,4,9	58.97 (± 12.115)	51.03 (± 22.210)		
CD45+CD3-CD16+CD69+CD107-; D1;1 h;n=1,3,1,5,4,9	61.59 (± 10.979)	55.68 (± 18.837)		
CD45+CD3-CD16+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11	63.25 (± 9.771)	58.44 (± 14.956)		
CD45+CD3-CD16+CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	57.86 (± 99999)		
CD45+CD3-CD16+CD69+CD107-; D8; n=1,3,0,5,4,8	65.52 (± 2.097)	43.74 (± 17.564)		
CD45+CD3-CD16+CD69+CD107-; D15;S1; n=1,3,1,5,4,9	63.57 (± 6.498)	57.42 (± 15.273)		
CD45+CD3-CD16+CD69+CD107-; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD69+CD107-; D29; n=1,3,1,4,4,8	55.64 (± 6.702)	58.48 (± 19.691)		
CD45+CD3-CD16+CD69+CD107-; FU; n=1,2,0,3,1,4	64.90 (± 99999)	53.69 (± 9.671)		
CD45+CD3-CD16+CD69+CD107-; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD69-CD107+; D1;pre n=1,3,1,5,4,9	0.43 (± 0.395)	0.36 (± 0.740)		

CD45+CD3-CD16+CD69-CD107+; D1;1 h;n=1,3,1,5,4,9	0.24 (± 0.441)	0.32 (± 0.494)		
CD45+CD3-CD16+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11	0.23 (± 0.403)	0.48 (± 1.014)		
CD45+CD3-CD16+CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	0.63 (± 99999)		
CD45+CD3-CD16+CD69-CD107+; D8; n=1,3,0,5,4,8	0.04 (± 0.041)	0.66 (± 0.524)		
CD45+CD3-CD16+CD69-CD107+; D15;S1; n=1,3,1,5,4,9	0.19 (± 0.236)	0.56 (± 0.890)		
CD45+CD3-CD16+CD69-CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD69-CD107+; D29; n=1,3,1,4,4,8	0.34 (± 0.241)	1.14 (± 1.844)		
CD45+CD3-CD16+CD69-CD107+; FU; n=1,2,0,3,1,4	0.09 (± 99999)	0.27 (± 0.324)		
CD45+CD3-CD16+CD69-CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD69-CD107-; D1;pre; n=1,3,1,5,4,9	17.07 (± 3.528)	23.98 (± 15.442)		
CD45+CD3-CD16+CD69-CD107-; D1;1 h;n=1,3,1,5,4,9	13.75 (± 3.880)	21.36 (± 16.671)		
CD45+CD3-CD16+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11	15.21 (± 4.603)	19.98 (± 11.842)		
CD45+CD3-CD16+CD69-CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	11.32 (± 99999)		
CD45+CD3-CD16+CD69-CD107-; D8; n=1,3,0,5,4,8	20.05 (± 2.014)	28.47 (± 21.443)		
CD45+CD3-CD16+CD69-CD107-; D15; S1;n=1,3,1,5,4,9	18.13 (± 7.060)	20.92 (± 19.349)		
CD45+CD3-CD16+CD69-CD107-; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD16+CD69-CD107-; D29; n=1,3,1,4,4,8	16.67 (± 6.466)	24.35 (± 16.239)		
CD45+CD3-CD16+CD69-CD107-; FU; n=1,2,0,3,1,4	23.54 (± 99999)	18.89 (± 19.247)		
CD45+CD3-CD16+CD69-CD107-; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD69+; D1;pre; n=1,3,1,5,4,9	77.94 (± 6.341)	71.81 (± 14.980)		
CD45+CD3-CD56+CD69+; D1;1 h;n=1,3,1,5,4,9	80.38 (± 5.074)	73.55 (± 18.249)		
CD45+CD3-CD56+CD69+;D1;6 h;n=1,3,1,5,4,11	79.33 (± 8.307)	74.28 (± 14.068)		
CD45+CD3-CD56+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	84.79 (± 99999)		
CD45+CD3-CD56+CD69+; D8; n=1,3,0,5,4,8	75.71 (± 6.039)	64.20 (± 17.380)		
CD45+CD3-CD56+CD69+; D15;S1; n=1,3,1,5,4,9	77.05 (± 1.250)	74.14 (± 18.976)		
CD45+CD3-CD56+CD69+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD69+; D29; n=1,3,1,4,4,8	78.39 (± 3.376)	72.21 (± 20.172)		
CD45+CD3-CD56+CD69+; FU; n=1,2,0,3,1,4	76.62 (± 99999)	75.78 (± 15.172)		
CD45+CD3-CD56+CD69+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD107+; D1; pre; n=1,3,1,5,4,9	20.36 (± 10.285)	15.35 (± 12.755)		
CD45+CD3-CD56+CD107+; D1;1 h;n=1,3,1,5,4,9	18.36 (± 8.295)	13.92 (± 14.620)		

CD45+CD3-CD56+CD107+;D1;6 h;n=1,3,1,5,4,11	19.50 (± 10.930)	17.82 (± 13.218)		
CD45+CD3-CD56+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	26.27 (± 99999)		
CD45+CD3-CD56+CD107+; D8; n=1,3,0,5,4,8	12.81 (± 2.027)	15.17 (± 12.783)		
CD45+CD3-CD56+CD107+; D15;S1; n=1,3,1,5,4,9	13.95 (± 4.221)	16.02 (± 10.352)		
CD45+CD3-CD56+CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD107+; D29; n=1,3,1,4,4,8	22.89 (± 7.527)	17.13 (± 5.406)		
CD45+CD3-CD56+CD107+; FU; n=1,2,0,3,1,4	11.46 (± 99999)	23.63 (± 17.232)		
CD45+CD3-CD56+CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD69+CD107+; D1; pre n=1,3,1,5,4,9	19.90 (± 9.878)	15.06 (± 12.804)		
CD45+CD3-CD56+CD69+CD107+; D1;1 h;n=1,3,1,5,4,9	17.72 (± 8.423)	13.60 (± 14.641)		
CD45+CD3-CD56+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11	19.15 (± 10.796)	15.67 (± 9.351)		
CD45+CD3-CD56+CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	25.81 (± 99999)		
CD45+CD3-CD56+CD69+CD107+; D8; n=1,3,0,5,4,8	12.69 (± 2.047)	14.33 (± 12.481)		
CD45+CD3-CD56+CD69+CD107+; D15;S1; n=1,3,1,5,4,9	13.80 (± 4.123)	15.58 (± 10.540)		
CD45+CD3-CD56+CD69+CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD69+CD107+; D29; n=1,3,1,4,4,8	22.55 (± 7.441)	15.59 (± 4.963)		
CD45+CD3-CD56+CD69+CD107+; FU; n=1,2,0,3,1,4	11.38 (± 99999)	23.00 (± 16.629)		
CD45+CD3-CD56+CD69+CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD69+CD107-; D1; pre; n=1,3,1,5,4,9	58.04 (± 12.938)	56.75 (± 10.180)		
CD45+CD3-CD56+CD69+CD107-; D1;1 h;n=1,3,1,5,4,9	62.66 (± 8.744)	59.95 (± 15.044)		
CD45+CD3-CD56+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11	60.18 (± 9.203)	58.62 (± 14.204)		
CD45+CD3-CD56+CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	58.99 (± 99999)		
CD45+CD3-CD56+CD69+CD107-; D15;S1; n=1,3,1,5,4,9	63.25 (± 5.044)	58.55 (± 14.595)		
CD45+CD3-CD56+CD69+CD107-; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD69+CD107-; D8; n=1,3,0,5,4,8	63.02 (± 5.005)	49.87 (± 13.422)		
CD45+CD3-CD56+CD69+CD107-; D29; n=1,3,1,4,4,8	55.84 (± 6.851)	56.62 (± 21.533)		
CD45+CD3-CD56+CD69+CD107-; FU; n=1,2,0,3,1,4	65.24 (± 99999)	52.78 (± 12.864)		
CD45+CD3-CD56+CD69+CD107-; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD69-CD107+; D1; pre; n=1,3,1,5,4,9	0.46 (± 0.425)	0.29 (± 0.558)		
CD45+CD3-CD56+CD69-CD107+; D1;1 h;n=1,3,1,5,4,9	0.64 (± 0.660)	0.32 (± 0.364)		
CD45+CD3-CD56+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11	0.35 (± 0.262)	2.15 (± 5.749)		

CD45+CD3-CD56+CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	0.46 (± 99999)		
CD45+CD3-CD56+CD69-CD107+; D8; n=1,3,0,5,4,8	0.11 (± 0.109)	0.84 (± 1.031)		
CD45+CD3-CD56+CD69-CD107+; D15;S1; n=1,3,1,5,4,9	0.15 (± 0.174)	0.44 (± 0.638)		
CD45+CD3-CD56+CD69-CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD69-CD107+; D29; n=1,3,1,4,4,8	0.35 (± 0.145)	1.54 (± 2.079)		
CD45+CD3-CD56+CD69-CD107+; FU; n=1,2,0,3,1,4	0.08 (± 99999)	0.62 (± 0.678)		
CD45+CD3-CD56+CD69-CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD69-CD107-; D1; pre; n=1,3,1,5,4,9	21.60 (± 6.379)	27.91 (± 14.759)		
CD45+CD3-CD56+CD69-CD107-; D1;1 h;n=1,3,1,5,4,9	18.99 (± 4.842)	26.13 (± 18.140)		
CD45+CD3-CD56+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11	20.36 (± 8.302)	23.56 (± 13.128)		
CD45+CD3-CD56+CD69-CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	14.75 (± 99999)		
CD45+CD3-CD56+CD69-CD107-; D8; n=1,3,0,5,4,8	24.18 (± 5.949)	34.96 (± 16.868)		
CD45+CD3-CD56+CD69-CD107-; D15;S1; n=1,3,1,5,4,9	22.81 (± 1.095)	25.43 (± 18.427)		
CD45+CD3-CD56+CD69-CD107-; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD69-CD107-; D29; n=1,3,1,4,4,8	21.27 (± 3.470)	26.26 (± 18.208)		
CD45+CD3-CD56+CD69-CD107-; FU; n=1,2,0,3,1,4	23.30 (± 99999)	23.60 (± 15.370)		
CD45+CD3-CD56+CD69-CD107-; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD16+CD69+; D1; pre; n=1,3,1,5,4,9	82.35 (± 3.605)	75.53 (± 16.495)		
CD45+CD3-CD56+CD16+CD69+; D1;1 h;n=1,3,1,5,4,9	85.57 (± 3.640)	77.45 (± 18.036)		
CD45+CD3-CD56+CD16+CD69+;D1;6 h;n=1,3,1,5,4,11	83.95 (± 4.687)	78.92 (± 13.044)		
CD45+CD3-CD56+CD16+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	87.90 (± 99999)		
CD45+CD3-CD56+CD16+CD69+; D8; n=1,3,0,5,4,8	79.75 (± 2.003)	70.62 (± 21.607)		
CD45+CD3-CD56+CD16+CD69+; D15;S1; n=1,3,1,5,4,9	80.67 (± 5.845)	79.09 (± 19.651)		
CD45+CD3-CD56+CD16+CD69+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD16+CD69+; D29; n=1,3,1,4,4,8	82.36 (± 4.976)	74.62 (± 18.799)		
CD45+CD3-CD56+CD16+CD69+; FU; n=1,2,0,3,1,4	76.73 (± 99999)	80.93 (± 19.159)		
CD45+CD3-CD56+CD16+CD69+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD16+CD107+; D1;pre; n=1,3,1,5,4,9	22.71 (± 12.190)	23.18 (± 31.567)		
CD45+CD3-CD56+CD16+CD107+; D1;1 h;n=1,3,1,5,4,9	23.33 (± 14.182)	20.40 (± 26.478)		
CD45+CD3-CD56+CD16+CD107+;D1;6 h;n=1,3,1,5,4,11	20.47 (± 12.384)	19.35 (± 17.934)		
CD45+CD3-CD56+CD16+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	30.57 (± 99999)		

CD45+CD3-CD56+CD16+CD107+; D8; n=1,3,0,5,4,8	13.90 (± 2.089)	26.69 (± 33.377)		
CD45+CD3-CD56+CD16+CD107+; D15;S1; n=1,3,1,5,4,9	14.72 (± 4.613)	21.04 (± 17.138)		
CD45+CD3-CD56+CD16+CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD56+CD16+CD107+; D29; n=1,3,1,4,4,8	25.75 (± 9.873)	18.09 (± 7.210)		
CD45+CD3-CD56+CD16+CD107+; FU; n=1,2,0,3,1,4	11.68 (± 99999)	25.61 (± 14.702)		
CD45+CD3-CD56+CD16+CD107+; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CDX241; D1;pre; n=1,3,1,5,4,9	22.27 (± 11.808)	22.97 (± 31.676)		
CDX241; D1;1h;n=1,3,1,5,4,9	23.12 (± 14.060)	20.23 (± 26.492)		
CDX241; D1;6h;n=1,3,1,5,4,11	20.23 (± 12.033)	19.06 (± 18.044)		
CDX241; D2; n=0,0,1,2,0,1	99999 (± 99999)	29.94 (± 99999)		
CDX241; D8; n=1,3,0,5,4,8	13.88 (± 2.075)	26.20 (± 33.362)		
CDX241; D15;S1;n=1,3,1,5,4,9	14.55 (± 4.521)	20.62 (± 17.353)		
CDX241; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CDX241; D29; n=1,3,1,4,4,8	25.56 (± 9.917)	16.64 (± 6.597)		
CDX241; FU; n=1,2,0,3,1,4	11.59 (± 99999)	25.41 (± 14.820)		
CDX241; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CDX243; D1; pre; n=1,3,1,5,4,9	60.08 (± 11.697)	52.56 (± 22.645)		
CDX243; D1;1h; n=1,3,1,5,4,9	62.45 (± 11.395)	57.22 (± 19.058)		
CDX243;D1;6h; n=1,3,1,5,4,11	63.72 (± 9.993)	59.86 (± 14.378)		
CDX243; D2; n=0,0,1,2,0,1	99999 (± 99999)	57.96 (± 99999)		
CDX243; D8; n=1,3,0,5,4,8	65.87 (± 2.821)	44.43 (± 22.911)		
CDX243; D15;S1; n=1,3,1,5,4,9	66.13 (± 9.524)	58.47 (± 16.070)		
CDX243; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CDX243; D29; n=1,3,1,4,4,8	56.80 (± 5.697)	57.98 (± 21.467)		
CDX243; FU;n=1,2,0,3,1,4	65.13 (± 99999)	55.52 (± 9.421)		
CDX243; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CDX244; D1; pre; n=1,3,1,5,4,9	0.45 (± 0.422)	0.21 (± 0.505)		
CDX244; D1;1h;n=1,3,1,5,4,9	0.22 (± 0.391)	0.17 (± 0.319)		
CDX244; D1;6h;n=1,3,1,5,4,11	0.24 (± 0.423)	0.30 (± 0.682)		
CDX244; D2; n=0,0,1,2,0,1	99999 (± 99999)	0.64 (± 99999)		
CDX244; D8; n=1,3,0,5,4,8	0.02 (± 0.045)	0.49 (± 0.601)		
CDX244; D15;S1;n=1,3,1,5,4,9	0.71 (± 0.204)	0.42 (± 0.632)		
CDX244; D15;S2n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		

CDX244; D29; n=1,3,1,4,4,8	0.19 (± 0.194)	1.46 (± 1.849)		
CDX244; FU;n=1,2,0,3,1,4	0.09 (± 99999)	0.20 (± 0.189)		
CDX244; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CDX245; D1; pre; n=1,3,1,5,4,9	17.21 (± 3.797)	24.26 (± 16.218)		
CDX245; D1; 1h; n=1,3,1,5,4,9	14.21 (± 3.682)	22.37 (± 17.894)		
CDX245; D1; 6h; n=1,3,1,5,4,11	15.82 (± 4.876)	20.79 (± 12.726)		
CDX245; D2; n=0,0,1,2,0,1	99999 (± 99999)	11.46 (± 99999)		
CDX245; D8; n=1,3,0,5,4,8	20.23 (± 1.977)	28.88 (± 21.510)		
CDX245; D15; S1; n=1,3,1,5,4,9	19.16 (± 5.695)	20.48 (± 19.116)		
CDX245; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CDX245; D29; n=1,3,1,4,4,8	17.45 (± 4.991)	23.93 (± 16.995)		
CDX245; FU; n=1,2,0,3,1,4	23.19 (± 99999)	18.88 (± 18.996)		
CDX245; USC; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+CD69+;D1pre; n=1,3,1,5,4,9	80.50 (± 5.553)	72.52 (± 20.777)		
CD45+CD3+CD56+CD69+;D1;1 h;n=1,3,1,5,4,9	76.76 (± 7.819)	69.96 (± 23.711)		
CD45+CD3+CD56+CD69+;D1;6 h;n=1,3,1,5,4,11	77.96 (± 9.405)	73.92 (± 20.707)		
CD45+CD3+CD56+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	81.34 (± 99999)		
CD45+CD3+CD56+CD69+; D8; n=1,3,0,5,4,8	77.76 (± 3.671)	71.42 (± 17.583)		
CD45+CD3+CD56+CD69+; D15;S1; n=1,3,1,5,4,9	75.78 (± 3.311)	72.29 (± 22.078)		
CD45+CD3+CD56+CD69+;D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+CD69+; D29; n=1,3,1,4,4,8	79.47 (± 4.516)	73.25 (± 19.837)		
CD45+CD3+CD56+CD69+; FU;n=1,2,0,3,1,4	78.84 (± 99999)	78.73 (± 13.208)		
CD45+CD3+CD56+CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+CD107+;D1pre; n=1,3,1,5,4,9	25.59 (± 10.582)	21.94 (± 11.569)		
CD45+CD3+CD56+CD107+;D1;1 h;n=1,3,1,5,4,9	20.17 (± 7.408)	19.38 (± 9.838)		
CD45+CD3+CD56+CD107+;D1;6 h;n=1,3,1,5,4,11	18.38 (± 7.558)	27.83 (± 16.580)		
CD45+CD3+CD56+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	21.27 (± 99999)		
CD45+CD3+CD56+CD107+; D8; n=1,3,0,5,4,8	23.85 (± 15.031)	25.37 (± 9.055)		
CD45+CD3+CD56+CD107+; D15; S1;n=1,3,1,5,4,9	22.75 (± 9.361)	24.77 (± 13.389)		
CD45+CD3+CD56+CD107+;D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+CD107+; D29; n=1,3,1,4,4,8	26.64 (± 16.501)	25.47 (± 7.825)		
CD45+CD3+CD56+CD107+; FU;n=1,2,0,3,1,4	16.40 (± 99999)	26.92 (± 16.312)		

CD45+CD3+CD56+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+CD69+CD107+;D1; pre; n=1,3,1,5,4,9	24.97 (± 10.148)	21.16 (± 11.995)		
CD45+CD3+CD56+CD69+CD107+;D1; 1 h;n=1,3,1,5,4,9	19.58 (± 6.559)	18.93 (± 9.947)		
CD45+CD3+CD56+CD69+CD107+;D1; 6 h;n=1,3,1,5,4,11	17.89 (± 7.034)	26.49 (± 16.563)		
CD45+CD3+CD56+CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	20.90 (± 99999)		
CD45+CD3+CD56+CD69+CD107+; D8; n=1,3,0,5,4,8	23.10 (± 14.534)	24.68 (± 9.353)		
CD45+CD3+CD56+CD69+CD107+; D15;S1; n=1,3,1,5,4,9	22.25 (± 9.194)	23.91 (± 13.531)		
CD45+CD3+CD56+CD69+CD107+;D15 ;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+CD69+CD107+; D29; n=1,3,1,4,4,8	25.87 (± 15.887)	23.72 (± 7.717)		
CD45+CD3+CD56+CD69+CD107+; FU;n=1,2,0,3,1,4	15.87 (± 99999)	26.51 (± 16.034)		
CD45+CD3+CD56+CD69+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+CD69+CD107-;D1; pre; n=1,3,1,5,4,9	55.53 (± 15.219)	51.35 (± 15.196)		
CD45+CD3+CD56+CD69+CD107-;D1;1 h;n=1,3,1,5,4,9	57.19 (± 10.200)	51.04 (± 17.281)		
CD45+CD3+CD56+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11	60.07 (± 13.763)	47.43 (± 15.287)		
CD45+CD3+CD56+CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	60.45 (± 99999)		
CD45+CD3+CD56+CD69+CD107-; D8; n=1,3,0,5,4,8	54.67 (± 12.323)	46.74 (± 9.237)		
CD45+CD3+CD56+CD69+CD107-; D15;S1; n=1,3,1,5,4,9	53.53 (± 10.408)	48.38 (± 17.947)		
CD45+CD3+CD56+CD69+CD107- ;D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+CD69+CD107-; D29; n=1,3,1,4,4,8	53.61 (± 15.433)	49.53 (± 16.556)		
CD45+CD3+CD56+CD69+CD107-; FU;n=1,2,0,3,1,4	62.96 (± 99999)	52.22 (± 5.130)		
CD45+CD3+CD56+CD69+CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+CD69- CD107+;D1pre; n=1,3,1,5,4,9	0.62 (± 0.761)	0.77 (± 1.157)		
CD45+CD3+CD56+CD69-CD107+;D1;1 h;n=1,3,1,5,4,9	0.59 (± 0.889)	0.45 (± 0.501)		
CD45+CD3+CD56+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11	0.49 (± 0.666)	1.35 (± 2.225)		
CD45+CD3+CD56+CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	0.37 (± 99999)		
CD45+CD3+CD56+CD69-CD107+; D8; n=1,3,0,5,4,8	0.75 (± 0.573)	0.69 (± 0.656)		
CD45+CD3+CD56+CD69-CD107+; D15;S1;n=1,3,1,5,4,9	0.51 (± 0.307)	0.87 (± 1.194)		
CD45+CD3+CD56+CD69- CD107+;D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+CD69-CD107+; D29; n=1,3,1,4,4,8	0.77 (± 0.697)	1.75 (± 2.925)		
CD45+CD3+CD56+CD69-CD107+; FU;n=1,2,0,3,1,4	0.53 (± 99999)	0.41 (± 0.407)		
CD45+CD3+CD56+CD69-CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		

CD45+CD3+CD56+CD69-CD107-; ;D1pre; n=1,3,1,5,4,9	18.88 (± 5.007)	26.71 (± 19.740)		
CD45+CD3+CD56+CD69-CD107-; ;D1;1h;n=1,3,1,5,4,9	22.65 (± 7.631)	29.59 (± 23.473)		
CD45+CD3+CD56+CD69-CD107-; ;D1;6h;n=1,3,1,5,4,11	21.55 (± 8.954)	24.74 (± 19.457)		
CD45+CD3+CD56+CD69-CD107-; ; D2; n=0,0,1,2,0,1	99999 (± 99999)	18.28 (± 99999)		
CD45+CD3+CD56+CD69-CD107-; ; D8; n=1,3,0,5,4,8	21.49 (± 4.140)	27.89 (± 17.180)		
CD45+CD3+CD56+CD69-CD107-; ; D15;S1; n=1,3,1,5,4,9	23.72 (± 3.040)	26.84 (± 21.388)		
CD45+CD3+CD56+CD69-CD107-; ;D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD56+CD69-CD107-; ; D29; n=1,3,1,4,4,8	19.76 (± 4.920)	25.00 (± 18.022)		
CD45+CD3+CD56+CD69-CD107-; ; FU;n=1,2,0,3,1,4	20.63 (± 99999)	20.86 (± 13.394)		
CD45+CD3+CD56+CD69-CD107-; ; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD69+;D1pre; n=1,3,1,5,4,9	69.48 (± 7.473)	64.41 (± 15.841)		
CD45+CD3+CD8+CD69+;D1;1 h;n=1,3,1,5,4,9	69.27 (± 10.664)	62.62 (± 18.568)		
CD45+CD3+CD8+CD69+;D1;6 h;n=1,3,1,5,4,11	69.44 (± 10.476)	64.10 (± 16.568)		
CD45+CD3+CD8+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	73.16 (± 99999)		
CD45+CD3+CD8+CD69+; D8; n=1,3,0,5,4,8	69.15 (± 2.032)	59.81 (± 14.230)		
CD45+CD3+CD8+CD69+; D15;S1; n=1,3,1,5,4,9	65.46 (± 2.301)	58.44 (± 20.646)		
CD45+CD3+CD8+CD69+; D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD69+; D29; n=1,3,1,4,4,8	70.42 (± 3.658)	60.96 (± 16.314)		
CD45+CD3+CD8+CD69+; FU;n=1,2,0,3,1,4	70.80 (± 99999)	70.63 (± 13.052)		
CD45+CD3+CD8+CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD107+;D1pre; n=1,3,1,5,4,9	19.50 (± 5.678)	12.96 (± 7.622)		
CD45+CD3+CD8+CD107+;D1;1 h;n=1,3,1,5,4,9	17.86 (± 7.915)	12.10 (± 9.816)		
CD45+CD3+CD8+CD107+;D1;6 h;n=1,3,1,5,4,11	17.74 (± 6.679)	14.58 (± 7.973)		
CD45+CD3+CD8+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	15.65 (± 99999)		
CD45+CD3+CD8+CD107+; D8; n=1,3,0,5,4,8	19.58 (± 10.034)	13.53 (± 7.177)		
CD45+CD3+CD8+CD107+; D15; S1;n=1,3,1,5,4,9	18.52 (± 6.515)	14.52 (± 11.560)		
CD45+CD3+CD8+CD107+; D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD107+; D29; n=1,3,1,4,4,8	22.28 (± 10.800)	16.01 (± 7.377)		
CD45+CD3+CD8+CD107+; FU;n=1,2,0,3,1,4	20.65 (± 99999)	24.54 (± 20.530)		
CD45+CD3+CD8+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD69+CD107+;D1pr e; n=1,3,1,5,4,9	18.89 (± 5.513)	12.42 (± 7.519)		

CD45+CD3+CD8+CD69+CD107+;D1;1h;n=1,3,1,5,4,9	17.10 (± 7.592)	11.51 (± 9.671)		
CD45+CD3+CD8+CD69+CD107+;D1;6h;n=1,3,1,5,4,11	16.83 (± 6.502)	13.49 (± 8.242)		
CD45+CD3+CD8+CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	15.59 (± 99999)		
CD45+CD3+CD8+CD69+CD107+; D8; n=1,3,0,5,4,8	18.62 (± 9.229)	12.58 (± 6.811)		
CD45+CD3+CD8+CD69+CD107+; D15;S1; n=1,3,1,5,4,9	17.46 (± 5.818)	13.79 (± 11.461)		
CD45+CD3+CD8+CD69+CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD69+CD107+; D29; n=1,3,1,4,4,8	21.18 (± 9.942)	14.79 (± 7.086)		
CD45+CD3+CD8+CD69+CD107+; FU;n=1,2,0,3,1,4	20.35 (± 99999)	22.91 (± 18.370)		
CD45+CD3+CD8+CD69+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD69+CD107-;D1pre; n=1,3,1,5,4,9	50.59 (± 11.155)	51.99 (± 13.129)		
CD45+CD3+CD8+CD69+CD107-;D1;1h;n=1,3,1,5,4,9	52.17 (± 7.570)	51.12 (± 15.653)		
CD45+CD3+CD8+CD69+CD107-;D1;6h;n=1,3,1,5,4,11	52.61 (± 7.942)	50.61 (± 11.996)		
CD45+CD3+CD8+CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	57.57 (± 99999)		
CD45+CD3+CD8+CD69+CD107-; D8; n=1,3,0,5,4,8	50.52 (± 8.995)	47.22 (± 12.334)		
CD45+CD3+CD8+CD69+CD107-; D15; S1;n=1,3,1,5,4,9	47.99 (± 7.314)	44.65 (± 18.062)		
CD45+CD3+CD8+CD69+CD107-; D15; S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD69+CD107-; D29; n=1,3,1,4,4,8	49.25 (± 12.319)	46.17 (± 14.907)		
CD45+CD3+CD8+CD69+CD107-; FU;n=1,2,0,3,1,4	50.44 (± 99999)	47.72 (± 13.474)		
CD45+CD3+CD8+CD69+CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD69-CD107+;D1pre; n=1,3,1,5,4,9	0.61 (± 0.493)	0.54 (± 0.575)		
CD45+CD3+CD8+CD69-CD107+;D1;1h;n=1,3,1,5,4,9	0.76 (± 0.919)	0.59 (± 0.605)		
CD45+CD3+CD8+CD69-CD107+;D1;6h;n=1,3,1,5,4,11	0.91 (± 0.629)	1.09 (± 1.070)		
CD45+CD3+CD8+CD69-CD107+; D8; n=1,3,0,5,4,8	0.96 (± 1.007)	0.95 (± 1.058)		
CD45+CD3+CD8+CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	0.06 (± 99999)		
CD45+CD3+CD8+CD69-CD107+; D15;S1;n=1,3,1,5,4,9	1.05 (± 0.920)	0.73 (± 0.435)		
CD45+CD3+CD8+CD69-CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD69-CD107+; D29; n=1,3,1,4,4,8	1.10 (± 0.919)	1.22 (± 1.347)		
CD45+CD3+CD8+CD69-CD107+; FU;n=1,2,0,3,1,4	0.29 (± 99999)	1.63 (± 2.326)		
CD45+CD3+CD8+CD69-CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD69-CD107-;D1pre; n=1,3,1,5,4,9	29.92 (± 7.082)	35.04 (± 15.444)		
CD45+CD3+CD8+CD69-CD107-;D1;1h;n=1,3,1,5,4,9	29.97 (± 10.290)	36.79 (± 18.243)		

CD45+CD3+CD8+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11	29.65 (± 10.132)	34.81 (± 15.738)		
CD45+CD3+CD8+CD69-CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	26.77 (± 99999)		
CD45+CD3+CD8+CD69-CD107-; D8; n=1,3,0,5,4,8	29.90 (± 2.006)	39.24 (± 13.864)		
CD45+CD3+CD8+CD69-CD107-; D15;S1; n=1,3,1,5,4,9	33.49 (± 1.695)	40.83 (± 20.434)		
CD45+CD3+CD8+CD69-CD107-; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8+CD69-CD107-; D29; n=1,3,1,4,4,8	28.48 (± 3.302)	37.82 (± 15.640)		
CD45+CD3+CD8+CD69-CD107-; FU;n=1,2,0,3,1,4	28.91 (± 99999)	27.74 (± 14.176)		
CD45+CD3+CD8+CD69-CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD69+;D1pre; n=1,3,1,5,4,9	63.78 (± 9.470)	57.37 (± 19.984)		
CD45+CD3+CD69+;D1;1 h;n=1,3,1,5,4,9	62.71 (± 13.023)	55.80 (± 21.386)		
CD45+CD3+CD69+;D1;6 h;n=1,3,1,5,4,11	63.26 (± 12.922)	60.07 (± 19.171)		
CD45+CD3+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	62.93 (± 99999)		
CD45+CD3+CD69+; D8; n=1,3,0,5,4,8	65.73 (± 6.597)	51.29 (± 13.826)		
CD45+CD3+CD69+; D15;S1; n=1,3,1,5,4,9	58.46 (± 3.564)	53.38 (± 21.988)		
CD45+CD3+CD69+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD69+; D29; n=1,3,1,4,4,8	63.88 (± 5.978)	53.68 (± 19.308)		
CD45+CD3+CD69+; FU;n=1,2,0,3,1,4	64.95 (± 99999)	67.21 (± 17.378)		
CD45+CD3+CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD107+;D1pre; n=1,3,1,5,4,9	8.92 (± 4.982)	8.99 (± 4.894)		
CD45+CD3+CD107+;D1;1 h;n=1,3,1,5,4,9	6.79 (± 3.717)	7.91 (± 4.880)		
CD45+CD3+CD107+;D1;6 h;n=1,3,1,5,4,11	7.25 (± 3.529)	11.04 (± 4.474)		
CD45+CD3+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	9.61 (± 99999)		
CD45+CD3+CD107+; D8; n=1,3,0,5,4,8	9.81 (± 6.276)	10.61 (± 7.576)		
CD45+CD3+CD107+; D15;S1; n=1,3,1,5,4,9	8.13 (± 4.504)	10.75 (± 6.692)		
CD45+CD3+CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD107+; D29; n=1,3,1,4,4,8	10.30 (± 6.320)	10.79 (± 4.881)		
CD45+CD3+CD107+; FU;n=1,2,0,3,1,4	5.11 (± 99999)	12.44 (± 10.953)		
CD45+CD3+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD69+CD107+;D1pre; n=1,3,1,5,4,9	8.62 (± 4.781)	8.55 (± 4.996)		
CD45+CD3+CD69+CD107+;D1;1 h;n=1,3,1,5,4,9	6.42 (± 3.287)	7.43 (± 4.929)		
CD45+CD3+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11	6.89 (± 3.217)	10.03 (± 4.618)		

CD45+CD3+CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	9.57 (± 99999)		
CD45+CD3+CD69+CD107+; D8; n=1,3,0,5,4,8	9.36 (± 5.904)	9.58 (± 6.752)		
CD45+CD3+CD69+CD107+; D15;S1 ; n=1,3,1,5,4,9	7.74 (± 4.077)	10.13 (± 6.879)		
CD45+CD3+CD69+CD107+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD69+CD107+; D29; n=1,3,1,4,4,8	9.88 (± 5.888)	9.56 (± 4.499)		
CD45+CD3+CD69+CD107+; FU;n=1,2,0,3,1,4	4.98 (± 99999)	11.70 (± 9.912)		
CD45+CD3+CD69+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD69+CD107-;D1pre; n=1,3,1,5,4,9	55.15 (± 13.699)	48.82 (± 16.871)		
CD45+CD3+CD69+CD107-;D1;1 h;n=1,3,1,5,4,9	56.29 (± 13.709)	48.37 (± 18.392)		
CD45+CD3+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11	56.37 (± 14.071)	50.04 (± 16.622)		
CD45+CD3+CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	53.35 (± 99999)		
CD45+CD3+CD69+CD107-; D8; n=1,3,0,5,4,8	56.37 (± 8.661)	41.72 (± 11.909)		
CD45+CD3+CD69+CD107-; D15; S1; n=1,3,1,5,4,9	50.72 (± 6.589)	43.25 (± 18.831)		
CD45+CD3+CD69+CD107-; D15; S2;n=0, 0, 1, 0, 0, 0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD69+CD107-; D29; n=1,3,1,4,4,8	54.00 (± 11.624)	44.11 (± 17.898)		
CD45+CD3+CD69+CD107-; FU;n=1,2,0,3,1,4	59.97 (± 99999)	55.52 (± 16.825)		
CD45+CD3+CD69+CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD69-CD107+;D1pre; n=1,3,1,5,4,9	0.30 (± 0.324)	0.44 (± 0.537)		
CD45+CD3+CD69-CD107+;D1;1 h;n=1,3,1,5,4,9	0.36 (± 0.477)	0.48 (± 0.459)		
CD45+CD3+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11	0.36 (± 0.349)	1.01 (± 1.233)		
CD45+CD3+CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	0.03 (± 99999)		
CD45+CD3+CD69-CD107+; D8; n=1,3,0,5,4,8	0.45 (± 0.458)	1.04 (± 1.201)		
CD45+CD3+CD69-CD107+; D15; S1; n=1,3,1,5,4,9	0.39 (± 0.439)	0.62 (± 0.460)		
CD45+CD3+CD69-CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD69-CD107+; D29; n=1,3,1,4,4,8	0.42 (± 0.449)	1.22 (± 1.608)		
CD45+CD3+CD69-CD107+; FU;n=1,2,0,3,1,4	0.13 (± 99999)	0.75 (± 1.090)		
CD45+CD3+CD69-CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD69-CD107-;D1pre; n=1,3,1,5,4,9	35.93 (± 9.242)	42.20 (± 19.537)		
CD45+CD3+CD69-CD107-;D1;1 h;n=1,3,1,5,4,9	36.93 (± 12.789)	43.72 (± 21.074)		
CD45+CD3+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11	36.38 (± 12.700)	38.92 (± 18.214)		
CD45+CD3+CD69-CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	37.04 (± 99999)		

CD45+CD3+CD69-CD107-; D8; n=1,3,0,5,4,8	33.83 (± 6.576)	47.67 (± 13.646)		
CD45+CD3+CD69-CD107-; D15;S1; n=1,3,1,5,4,9	41.15 (± 3.409)	46.00 (± 21.556)		
CD45+CD3+CD69-CD107-; D15; S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD69-CD107-; D29; n=1,3,1,4,4,8	35.70 (± 5.601)	45.10 (± 18.361)		
CD45+CD3+CD69-CD107-; FU;n=1,2,0,3,1,4	34.92 (± 99999)	32.05 (± 17.570)		
CD45+CD3+CD69-CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-CD69+;D1pre; n=1,3,1,5,4,9	58.78 (± 9.546)	52.12 (± 20.035)		
CD45+CD3+CD8-CD69+;D1;1 h;n=1,3,1,5,4,9	59.04 (± 12.906)	51.86 (± 22.844)		
CD45+CD3+CD8-CD69+;D1;6 h;n=1,3,1,5,4,11	59.18 (± 13.744)	56.19 (± 18.029)		
CD45+CD3+CD8-CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	51.49 (± 99999)		
CD45+CD3+CD8-CD69+; D8; n=1,3,0,5,4,8	64.59 (± 10.317)	42.80 (± 13.006)		
CD45+CD3+CD8-CD69+; D15; S1;n=1,3,1,5,4,9	53.99 (± 7.004)	49.92 (± 22.128)		
CD45+CD3+CD8-CD69+; D15; S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-CD69+; D29; n=1,3,1,4,4,8	59.41 (± 7.751)	50.71 (± 19.479)		
CD45+CD3+CD8-CD69+; FU;n=1,2,0,3,1,4	64.72 (± 99999)	59.43 (± 17.448)		
CD45+CD3+CD8-CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-CD107+;D1pre; n=1,3,1,5,4,9	9.40 (± 9.095)	8.89 (± 7.406)		
CD45+CD3+CD8-CD107+;D1;1 h;n=1,3,1,5,4,9	10.14 (± 11.064)	5.52 (± 3.023)		
CD45+CD3+CD8-CD107+;D1;6 h;n=1,3,1,5,4,11	11.10 (± 12.927)	8.49 (± 3.930)		
CD45+CD3+CD8-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	12.25 (± 99999)		
CD45+CD3+CD8-CD107+; D8; n=1,3,0,5,4,8	6.89 (± 3.550)	7.20 (± 3.406)		
CD45+CD3+CD8-CD107+; D15; S1;n=1,3,1,5,4,9	6.66 (± 4.113)	10.03 (± 7.687)		
CD45+CD3+CD8-CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-CD107+; D29; n=1,3,1,4,4,8	8.29 (± 3.475)	8.07 (± 5.728)		
CD45+CD3+CD8-CD107+; FU;n=1,2,0,3,1,4	4.78 (± 99999)	16.10 (± 11.466)		
CD45+CD3+CD8-CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8- CD69+CD107+;D1pre; n=1,3,1,5,4,9	8.70 (± 8.036)	8.49 (± 7.511)		
CD45+CD3+CD8-CD69+CD107+;D1;1 h;n=1,3,1,5,4,9	9.37 (± 9.954)	5.08 (± 3.208)		
CD45+CD3+CD8-CD69+CD107+;D1;6 h;n=1,3,1,5,4,11	10.26 (± 11.433)	7.64 (± 3.879)		
CD45+CD3+CD8-CD69+CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	11.90 (± 99999)		
CD45+CD3+CD8-CD69+CD107+; D8; n=1,3,0,5,4,8	6.68 (± 3.439)	6.35 (± 3.062)		

CD45+CD3+CD8-CD69+CD107+; D15; S1;n=1,3,1,5,4,9	6.42 (± 3.978)	9.27 (± 7.216)		
CD45+CD3+CD8-CD69+CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-CD69+CD107+; D29; n=1,3,1,4,4,8	8.03 (± 3.389)	6.92 (± 4.718)		
CD45+CD3+CD8-CD69+CD107+; FU;n=1,2,0,3,1,4	4.63 (± 99999)	14.87 (± 10.444)		
CD45+CD3+CD8-CD69+CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-CD69+CD107-;D1pre; n=1,3,1,5,4,9	50.08 (± 9.719)	43.63 (± 15.780)		
CD45+CD3+CD8-CD69+CD107-;D1;1 h;n=1,3,1,5,4,9	49.68 (± 9.756)	46.78 (± 20.420)		
CD45+CD3+CD8-CD69+CD107-;D1;6 h;n=1,3,1,5,4,11	48.93 (± 11.819)	48.55 (± 16.115)		
CD45+CD3+CD8-CD69+CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	39.59 (± 99999)		
CD45+CD3+CD8-CD69+CD107-; D8; n=1,3,0,5,4,8	57.91 (± 9.965)	36.45 (± 12.237)		
CD45+CD3+CD8-CD69+CD107-; D15;S1; n=1,3,1,5,4,9	47.58 (± 6.986)	40.65 (± 18.749)		
CD45+CD3+CD8-CD69+CD107-; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-CD69+CD107-; D29; n=1,3,1,4,4,8	51.37 (± 5.812)	43.79 (± 19.299)		
CD45+CD3+CD8-CD69+CD107-; FU;n=1,2,0,3,1,4	60.09 (± 99999)	44.55 (± 12.109)		
CD45+CD3+CD8-CD69+CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-CD69-CD107+;D1pre; n=1,3,1,5,4,9	0.70 (± 1.089)	0.41 (± 0.541)		
CD45+CD3+CD8-CD69-CD107+;D1;1 h;n=1,3,1,5,4,9	0.77 (± 1.174)	0.43 (± 0.496)		
CD45+CD3+CD8-CD69-CD107+;D1;6 h;n=1,3,1,5,4,11	0.85 (± 1.537)	0.85 (± 1.277)		
CD45+CD3+CD8-CD69-CD107+; D2; n=0,0,1,2,0,1	99999 (± 99999)	0.35 (± 99999)		
CD45+CD3+CD8-CD69-CD107+; D8; n=1,3,0,5,4,8	0.21 (± 0.194)	0.85 (± 0.855)		
CD45+CD3+CD8-CD69-CD107+; D15;S1; n=1,3,1,5,4,9	0.25 (± 0.179)	0.76 (± 0.966)		
CD45+CD3+CD8-CD69-CD107+; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-CD69-CD107+; D29; n=1,3,1,4,4,8	0.23 (± 0.117)	1.15 (± 1.764)		
CD45+CD3+CD8-CD69-CD107+; FU;n=1,2,0,3,1,4	0.15 (± 99999)	1.22 (± 1.319)		
CD45+CD3+CD8-CD69-CD107+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-CD69-CD107-;D1pre; n=1,3,1,5,4,9	40.53 (± 9.843)	47.48 (± 19.639)		
CD45+CD3+CD8-CD69-CD107-;D1;1 h;n=1,3,1,5,4,9	40.19 (± 13.401)	47.70 (± 22.541)		
CD45+CD3+CD8-CD69-CD107-;D1;6 h;n=1,3,1,5,4,11	39.98 (± 14.362)	42.96 (± 17.217)		
CD45+CD3+CD8-CD69-CD107-; D2; n=0,0,1,2,0,1	99999 (± 99999)	48.16 (± 99999)		
CD45+CD3+CD8-CD69-CD107-; D8; n=1,3,0,5,4,8	35.20 (± 10.279)	56.36 (± 12.433)		
CD45+CD3+CD8-CD69-CD107-; D15;S1;n=1,3,1,5,4,9	45.76 (± 6.941)	49.32 (± 21.812)		

CD45+CD3+CD8-CD69-CD107-; D15;S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3+CD8-CD69-CD107-; D29; n=1,3,1,4,4,8	40.37 (± 7.766)	48.14 (± 18.661)		
CD45+CD3+CD8-CD69-CD107-; FU;n=1,2,0,3,1,4	35.13 (± 99999)	39.35 (± 17.631)		
CD45+CD3+CD8-CD69-CD107-; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD19+CD69+;D1pre; n=1,3,1,5,4,9	66.51 (± 16.098)	60.06 (± 14.370)		
CD45+CD3-CD19+CD69+;D1;1 h;n=1,3,1,5,4,9	67.42 (± 15.190)	61.79 (± 14.941)		
CD45+CD3-CD19+CD69+;D1;6 h;n=1,3,1,5,4,11	63.22 (± 18.089)	66.22 (± 20.094)		
CD45+CD3-CD19+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	58.57 (± 99999)		
CD45+CD3-CD19+CD69+; D8; n=1,3,0,5,4,8	66.95 (± 20.328)	52.90 (± 52.90)		
CD45+CD3-CD19+CD69+; D15;S1; n=1,3,1,5,4,9	61.50 (± 12.596)	61.77 (± 61.77)		
CD45+CD3-CD19+CD69+; D15;S2;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD3-CD19+CD69+; D29; n=1,3,1,4,4,8	65.80 (± 7.211)	61.49 (± 61.49)		
CD45+CD3-CD19+CD69+; FU;n=1,2,0,3,1,4	73.22 (± 99999)	70.54 (± 70.54)		
CD45+CD3-CD19+CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD14+CD69+;D1pre; n=1,3,1,5,4,9	99.19 (± 1.046)	99.39 (± 0.407)		
CD45+CD14+CD69+;D1;1 h;n=1,3,1,5,4,9	99.51 (± 0.658)	99.37 (± 0.725)		
CD45+CD14+CD69+;D1;6 h;n=1,3,1,5,4,11	99.11 (± 1.442)	99.24 (± 0.942)		
CD45+CD14+CD69+; D2; n=0,0,1,2,0,1	99999 (± 99999)	99.06 (± 99999)		
CD45+CD14+CD69+; D8; n=1,3,0,5,4,8	99.78 (± 0.241)	98.64 (± 1.993)		
CD45+CD14+CD69+; D15; S1; n=1,3,1,5,4,9	99.50 (± 0.435)	97.67 (± 3.444)		
CD45+CD14+CD69+; D15; S2; n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		
CD45+CD14+CD69+; D29; n=1,3,1,4,4,8	99.68 (± 0.225)	98.98 (± 1.950)		
CD45+CD14+CD69+; FU;n=1,2,0,3,1,4	99.47 (± 99999)	99.65 (± 0.288)		
CD45+CD14+CD69+; USC;n=0,0,1,0,0,0	99999 (± 99999)	99999 (± 99999)		

Notes:

[110] - PD Population

[111] - PD Population

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).

Adverse event reporting additional description:

AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

Reporting groups

Reporting group title	GSK2849330 1.4 mg/kg weekly
-----------------------	-----------------------------

Reporting group description:

Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days

Reporting group title	GSK2849330 3 mg/kg every 2 weeks
-----------------------	----------------------------------

Reporting group description:

Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

Reporting group title	GSK2849330 3 mg/kg weekly
-----------------------	---------------------------

Reporting group description:

Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.

Reporting group title	GSK2849330 10 mg/kg every 2 weeks
-----------------------	-----------------------------------

Reporting group description:

Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

Reporting group title	GSK2849330 30 mg/kg every 2 weeks
-----------------------	-----------------------------------

Reporting group description:

Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days

Reporting group title	GSK2849330 30 mg/kg weekly
-----------------------	----------------------------

Reporting group description:

Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).

Serious adverse events	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Investigations			

Ejection fraction decreased subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Escherichia sepsis subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Serious adverse events	GSK2849330 10 mg/kg every 2 weeks	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 5 (20.00%)	1 / 4 (25.00%)	3 / 14 (21.43%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events			
Investigations			
Ejection fraction decreased			

subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Escherichia sepsis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Urosepsis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	GSK2849330 1.4 mg/kg weekly	GSK2849330 3 mg/kg every 2 weeks	GSK2849330 3 mg/kg weekly
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 1 (100.00%)	3 / 3 (100.00%)	2 / 2 (100.00%)
Vascular disorders			
Hypertension			

subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vena cava thrombosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 1 (0.00%)	2 / 3 (66.67%)	2 / 2 (100.00%)
occurrences (all)	0	2	2
Non-cardiac chest pain			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	1 / 2 (50.00%)
occurrences (all)	0	1	2
Chest pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Malaise			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Discomfort			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Influenza like illness			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Mucosal inflammation			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 3 (33.33%) 1	0 / 2 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Reproductive system and breast disorders Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 3 (33.33%) 1	0 / 2 (0.00%) 0
Vulvovaginal pruritus subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 3 (33.33%) 1	0 / 2 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 3 (33.33%) 1	1 / 2 (50.00%) 1
Pleural effusion subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	1 / 2 (50.00%) 1
Asthma subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Pulmonary embolism subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Upper-airway cough syndrome			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Wheezing subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 3 (33.33%) 1	0 / 2 (0.00%) 0
Product issues Device dislocation subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	1 / 2 (50.00%) 1
Weight decreased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0

Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Thermal burn			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Aortic valve disease			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 1 (0.00%)	2 / 3 (66.67%)	2 / 2 (100.00%)
occurrences (all)	0	3	3
Dizziness			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Dysgeusia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	1 / 2 (50.00%) 1
Glaucoma subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Retinal haemorrhage subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	3 / 3 (100.00%) 4	1 / 2 (50.00%) 3
Abdominal pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	2 / 3 (66.67%) 2	0 / 2 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	1 / 2 (50.00%) 2
Vomiting subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 3 (33.33%) 1	1 / 2 (50.00%) 1
Constipation subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0
Abdominal distension subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	1 / 3 (33.33%) 1	0 / 2 (0.00%) 0
Abdominal pain upper			

subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Abdominal pain lower			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Oesophageal obstruction			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 1 (100.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Gingival pain			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Impaired gastric emptying			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Stomatitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Tongue coated			
subjects affected / exposed	1 / 1 (100.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			

Pruritus			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	4
Dry skin			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Blister			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Onychomadesis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	1 / 1 (100.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0

Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	1 / 2 (50.00%)
occurrences (all)	0	1	1
Back pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Arthralgia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Muscle twitching			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			

Lung infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Cystitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Otitis externa			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	1 / 2 (50.00%)
occurrences (all)	0	1	1
Hypomagnesaemia			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Hypoalbuminaemia			

subjects affected / exposed	0 / 1 (0.00%)	0 / 3 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Hypophagia			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Increased appetite			
subjects affected / exposed	0 / 1 (0.00%)	1 / 3 (33.33%)	0 / 2 (0.00%)
occurrences (all)	0	1	0

Non-serious adverse events	GSK2849330 10 mg/kg every 2 weeks	GSK2849330 30 mg/kg every 2 weeks	GSK2849330 30 mg/kg weekly
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 5 (100.00%)	4 / 4 (100.00%)	14 / 14 (100.00%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	4
Vena cava thrombosis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 5 (40.00%)	2 / 4 (50.00%)	10 / 14 (71.43%)
occurrences (all)	2	2	12
Non-cardiac chest pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	3
Chills			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Malaise			

subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Oedema peripheral			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	1
Chest discomfort			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Discomfort			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pruritus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 5 (20.00%)	1 / 4 (25.00%)	2 / 14 (14.29%)
occurrences (all)	1	1	2
Pleural effusion			

subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Asthma			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Nasal congestion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Pulmonary embolism			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Wheezing			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
Product issues			
Device dislocation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	2 / 5 (40.00%)	0 / 4 (0.00%)	2 / 14 (14.29%)
occurrences (all)	2	0	4
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	3 / 14 (21.43%)
occurrences (all)	1	0	4
Gamma-glutamyltransferase increased			

subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	4 / 14 (28.57%)
occurrences (all)	0	0	4
Weight decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	4 / 14 (28.57%)
occurrences (all)	0	0	5
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	3 / 14 (21.43%)
occurrences (all)	0	1	3
Blood bilirubin increased			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
Thermal burn			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Aortic valve disease			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	2	0	2
Dizziness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Dysgeusia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Paraesthesia			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	1 / 14 (7.14%) 1
Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	1 / 14 (7.14%) 1
Tremor subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 4 (0.00%) 0	0 / 14 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	1 / 14 (7.14%) 1
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	3 / 14 (21.43%) 3
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	1 / 14 (7.14%) 1
Glaucoma subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	1 / 14 (7.14%) 1
Retinal haemorrhage subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 4 (0.00%) 0	0 / 14 (0.00%) 0
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 2	3 / 4 (75.00%) 4	9 / 14 (64.29%) 12
Abdominal pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	4 / 14 (28.57%) 7
Nausea subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 2	0 / 4 (0.00%) 0	4 / 14 (28.57%) 4
Vomiting			

subjects affected / exposed	0 / 5 (0.00%)	3 / 4 (75.00%)	1 / 14 (7.14%)
occurrences (all)	0	4	2
Constipation			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	2 / 14 (14.29%)
occurrences (all)	0	1	3
Abdominal discomfort			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	1 / 14 (7.14%)
occurrences (all)	0	1	3
Abdominal distension			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Abdominal pain upper			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	1
Abdominal pain lower			
subjects affected / exposed	0 / 5 (0.00%)	2 / 4 (50.00%)	0 / 14 (0.00%)
occurrences (all)	0	2	0
Dry mouth			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Oesophageal obstruction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
Ascites			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Gingival pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Impaired gastric emptying			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Mouth ulceration			

subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Oral pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Tongue coated			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
Dry skin			
subjects affected / exposed	1 / 5 (20.00%)	1 / 4 (25.00%)	1 / 14 (7.14%)
occurrences (all)	1	1	1
Rash			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	3
Rash maculo-papular			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	3
Skin fissures			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Blister			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Dermatitis acneiform			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Onychomadesis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1

Psoriasis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Rash macular			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Skin ulcer			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	2 / 14 (14.29%)
occurrences (all)	0	1	4
Back pain			
subjects affected / exposed	1 / 5 (20.00%)	1 / 4 (25.00%)	3 / 14 (21.43%)
occurrences (all)	1	1	3
Arthralgia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 14 (0.00%)
occurrences (all)	0	2	0
Flank pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	1
Groin pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Muscle twitching			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Muscular weakness			

subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Musculoskeletal chest pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Neck pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Infections and infestations			
Lung infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Upper respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Cystitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Oral candidiasis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Otitis externa			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Paronychia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Urinary tract infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0

Viral infection subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 4 (0.00%) 0	0 / 14 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 2	2 / 4 (50.00%) 2	3 / 14 (21.43%) 3
Hypomagnesaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	1 / 14 (7.14%) 1
Hypoalbuminaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	0 / 14 (0.00%) 0
Hypokalaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	0 / 14 (0.00%) 0
Hypophagia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	0 / 14 (0.00%) 0
Increased appetite subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	0 / 14 (0.00%) 0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 September 2014	<p>Four molecularly-defined, tumor histology groups were added for study during Part 2. Additional inclusion criteria for participants in Part 2 were added to clarify the number of prior lines of therapy allowed for study entry and to require participants to undergo pre and on-treatment tumor biopsies. References to cohorts of participants in Part 2 were removed and replaced with groups of participants. An additional cohort of participants was added to Part 1. This cohort will receive weekly treatment with 30 milligrams per kilogram (mg/kg) GSK2849330, with an option to reduce dosing frequency to every 2 weeks after 24 weeks. The approximate number of participants in Part 1 was changed from 10 to 13, to accommodate the additional weekly cohort. The anticipated number of participants in Part 1 is now 34. The rationale for adding a weekly dosing regimen was added. The exclusion criteria for participants with untreated brain or meningeal metastases and participants treated for stable brain metastases were clarified. PK sampling times were revised for participants in Part 1 enrolled under this amendment and for participants enrolled in Part 2. Preclinical and nonclinical findings on HER3 antibodies from recent studies and abstracts were added, including the rationale for the tumor types selected for Part 2. The predicted half-life of GSK2849330 was changed from 8-9 days to 7 days at 30 mg/kg. The expected dosing frequency was changed from ≥ 2 weeks to 1-2 weeks. Preliminary noncompartmental and population PK parameters for the 1.4 mg/kg, 3 mg/kg, and 10 mg/kg doses were added. Permitted and prohibited medications (growth factors, anticoagulants, and corticosteroids) were clarified. The recommendations for management of diarrhea were expanded. The requirement for a sample for selected cytokines in participants experiencing suspected infusion-related reactions was added. The criterion for withholding of study treatment for QTc prolongation was clarified.</p>
09 January 2015	<p>The inclusion criteria were modified for Molecularly Defined Tumor Histology Groups 1, 2 and 4 in Part 2 to remove the statement that participants would be eligible for inclusion into the study if they had not received standard therapy when such therapy was not available to them commercially or via a clinical trial. The definition of DLT for participants with thrombocytopenia was expanded to include Grade 3 events of thrombocytopenia associated with bleeding in addition to all Grade 4 events. The statements regarding obtaining paired tumor biopsies have been modified to include that all biopsies should be obtained from tumor easily accessible to biopsy using a procedure that is safe for the participant. The total volume of blood to be collected within the first 30 days of participation has been modified to account for the increased PK sampling. Inconsistencies were corrected in the Time and Events Tables in Section 7. Minor grammatical and formatting changes were made throughout the document.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported